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Abstract 
The pyruvate dehydrogenase complex (PDC) is the rate limiting step in the entry of 
glucose derived pyruvate into the tricarboxylic acid (TCA) cycle.  As such it plays an 
important role in the control of the use of carbohydrate as the source of oxidative energy 
for skeletal muscle contraction.   
 
The first experimental chapter investigates the effect of dichloroacetate pre-treatment 
during low-intensity (<60% VO2max) exercise, below which it is suggested that 
increasing PDC activation and resting acetyl group availability via dichloroacetate (DCA) 
pre-treatment will be ineffective at reducing non-oxidative ATP production and 
improving contractile function. Despite a significant increase in both PDC activation 
(p<0.01) and acetylcarnitine availability (p<0.01) prior to the onset of exercise following 
DCA infusion, there was no difference in substrate level phosphorylation detected during 
exercise.   
 
The following experimental chapter examines the link between blood lactate 
concentration and the onset of the ventilatory threshold.  Infusion of DCA (50mg.kg-1) 
prior to the onset of incremental exercise lead to a significant reduction in resting blood 
lactate (p<0.05), but this was not preserved during the following bout of incremental 
cycling exercise commencing at 50% VO2max.  There was also no alteration in the onset 
of the ventilatory threshold detected after DCA pre-treatment. 
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The final experimental chapter has investigated the effect of DCA infusion (50 mg.kg-1) 
upon high-fat diet induced PDC inhibition during exercise.  During moderate cycling 
exercise (75% VO2max) DCA infusion reversed the high-fat induced inhibition of PDC 
activation.  DCA infusion reduced the metabolic inertia present at the onset of 
contraction, through both PDC activation and pooling of acetyl groups prior to 
contraction. 
 
This thesis has highlighted the role of the PDC as an important site of regulation of 
human skeletal muscle fuel metabolism, which may provide a novel target for the 
treatment of the metabolic syndrome. 
 
293 words. 
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Overview. 
The pyruvate dehydrogenase complex (PDC) catalyses the physiologically irreversible 
reaction that links glycolysis with several other biochemical pathways.  Within muscle, 
both skeletal and cardiac, and other tissues with high energy demands the Acetyl-CoA 
derived from this reaction enters the tricarboxylic acid (TCA) cycle for the subsequent 
synthesis of ATP (Randle, 1995).  Within tissues with a low energy demand (e.g. liver 
and adipose tissue) the acetyl-CoA generated is utilised for fatty acid and steroid 
synthesis.   
 
Within skeletal and cardiac muscle strict regulation of the actions of PDC are required, to 
ensure both efficient use of carbohydrate derived fuel for contraction and to meet the 
sudden rise in demand for ATP production during the rest-to-work transition. 
 
Work performed by Roberts and co-workers (Roberts et al, 2002b) has suggested a 
maximal exercise intensity at which pre-treatment with DCA is not of benefit to muscle 
metabolism, although it is unclear whether a lower threshold of exercise intensity exists.  
It has been assumed by some that the increase in ventilation measured at the ventilatory 
threshold is related to the similar increase in blood lactate concentration measured at that 
time.  Using dichloroacetate to reduce blood lactate concentration will allow for 
investigation of the relationship in healthy human volunteers between lactate 
concentration and the ventilatory threshold.  Putman and co-workers (Putman et al, 1993) 
identified that a reduction in dietary carbohydrate intake, or increase in dietary fat intake, 
leads to a blunting of PDC activation or inhibition of flux through PDC during 
 19 
subsequent exercise.  Given that DCA is known to increase skeletal muscle PDC 
activation at rest and during exercise, its effects in this population have not yet been 
investigated. 
 
Based upon the above research, the present thesis has examined the effects of PDC 
activation using the PDK inhibitor dichloroacetate (DCA) in three circumstances: 
i. during the rest-to-work transition in human skeletal muscle at low 
intensity exercise, 
ii. in an attempt to further investigate the mechanisms behind the onset of 
the ventilatory threshold and  
iii. in an attempt to overcome the blunting of muscle PDC activation seen 
after a reduction in dietary carbohydrate intake. 
 
To introduce the background to this project the literature review will initially describe the 
structure and function of PDC further, including its mechanism of regulation and the 
isoforms of pyruvate dehydrogenase kinase and phosphatase.  This will be followed by a 
discussion of the concept of metabolic inertia in skeletal muscle.  An overview of the 
GLIIHUHQWIXHOVXVHGDWGLIIHUHQWH[HUFLVHLQWHQVLWLHVDQGFDUQLWLQH¶VIXQFWLRQLVSUHVHQWHG
The review will then discuss the use of DCA as both an investigative tool in the 
exploration of metabolic inertia and a therapeutic tool in the treatment of conditions 
associated with hyperlactataemia.  Finally this review will consider FOXO and PPAR 
and their role in the regulation of PDC activity in skeletal muscle. 
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Literature Review. 
Pyruvate dehydrogenase complex - structure and function. 
The pyruvate dehydrogenase complex (PDC) is located on the mitochondrial inner 
membrane (Schnaitman and Greenawalt, 1968; Addink et al, 1972), where it oxidatively 
decarboxylates pyruvate to acetyl-CoA and carbon dioxide coupled with the reduction of 
NAD+ to NADH (see below).   
 
CH3COCOO- + CoASH + NAD+     CH3CO.CoA + CO2 + NADH 
 
PDC consists of three catalytic components, pyruvate dehydrogenase (E1), 
dihydrolipoamide transacetylase (E2) and dihydrolipoamide dehydrogenase (E3) (Reed 
and Hackert, 1990).  Each complex consists of a core of sixty E2 subunits, to which thirty 
E1 subunits are attached (at the E1-binding domain of E2).  Six to twelve E3 subunits are 
tightly bound to the E2 core through E3-binding protein (see Figure 1.1) 
 
These three enzymes decarboxylate and dehydrogenate pyruvate, in the presence of the 
essential cofactors thiamine pyrophosphate (TPP), free CoASH and NAD+.  The E1 
enzyme catalyses the decarboxylation of pyruvate and the subsequent reductive 
acetylation of the lipoyl moiety of E2.  This enzyme then catalyses the transfer of the 
acetyl group to the free CoASH cofactor.  The reduced lipoyl moiety of E2 is then re-
oxidised by E3, with NAD+ acting as the final acceptor of the reduced electron (Figure 
1.2).   
PDC 
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Figure 1.1 ± Scheme of a fragment of the mammalian pyruvate dehydrogenase complex 
structure (from Strumilo, 2005).  Only 2 subunits of E2 with E1 and E3 components are 
shown. 
 
Key: 
 
ID  Inner domain. 
BD  Binding domain. 
LD  Lipoyl domain. 
TDP  Thiamine diphosphate. 
FAD  Flavin adenine dinucleotide (oxidised form). 
PDK  Pyruvate dehydrogenase kinase. 
PDP  Pyruvate dehydrogenase phosphatase.  
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Figure 1.2 ± Sequence of reactions catalysed by the pyruvate dehydrogenase complex. 
 
Key: 
TPP  Thiamine pyrophosphate. 
Lip  Lipoic acid. 
FADH2 Flavin adenine dinucleotide (reduced form). 
FAD  Flavin adenine dinucleotide (oxidised form). 
NADH Nicotinamide adenine dinucleotide (reduced form). 
NAD  Nicotinamide adenine dinucleotide (oxidised form).
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 25 
PyruvDWHGHK\GURJHQDVH LV WHWUDPHULFFRQVLVWLQJRIHTXDOQXPEHUVRIĮDQGȕ VXEXQLWV
Į2ȕ27KHUROHVDQGLQWHJUDWLRQRIWKHVHVXEXQLWVLVSRRUO\XQGHUVWRRGEXWWKHĮ-residue 
is known to possess the serine residues that are the target for covalent modification by the 
FRPSOH[¶VLQWULQVLFUHJXODWRU\NLQDVHDQGSKRVSKDWDVHV\VWHPUHVSRQVLEOHIRUUHJXODWLRQ
of PDC activity and discussed later in this review.  The E1 component is responsible for 
catalysing the rate-limiting step of the overall PDC reaction (Cate et al, 1980).  Within 
mammals no pathways exist for the synthesis of pyruvate from Acetyl-CoA, therefore the 
control of this reaction is crucial to avoid depletion of carbohydrate derived carbon 
skeletons which cannot be re-synthesised by the body.  Regulation of PDC in skeletal 
muscle will be discussed later in this review. 
 
Dihydrolipoamide transacetylase forms the structural hub to which the E1, E3 and the 
intrinsic regulatory phosphatase and kinase bind.  The E2 enzyme catalyses the reversible 
acetyltransferase reaction and contains the lipoic acid residue that interacts with the 
active sites of the enzyme complex (Yeaman, 1989). 
 
Dihydrolipoamide dehydrogenase is a FAD-containing flavoprotein which contains the 
single disulphide bridge that undergoes oxidation and reduction during catalysis.  The E3 
enzyme is also linked to E3 binding protein which is thought to be responsible for linking 
PDC to the mitochondrial membrane protein. 
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Pyruvate dehydrogenase complex - regulation in skeletal muscle. 
At rest PDC activation is required to remain low, to prevent the utilisation of 
carbohydrate unnecessarily.  However at the onset of exercise a rapid increase in 
activation is required to provide acetyl units for entry into the TCA cycle.  Regulation of 
this enzyme is therefore essential for both the prompt use of carbohydrate derived energy 
stores within skeletal muscle at the onset of contraction and to avoid the consumption of 
carbohydrate stores when rapid ATP production is not required. 
 
There are two methods by which the activity of PDC can be regulated.  The first is by 
inhibition of the enzyme complex by its products NADH and acetyl-CoA, as well as 
activation of the enzyme complex by pyruvate, NAD+ and CoASH.  The second is by the 
covalent modification of the enzyme complex by its intrinsic kinase (pyruvate 
dehydrogenase kinase, PDK) and phosphatase (pyruvate dehydrogenase phosphatase, 
PDP) system, which will be discussed later. 
 
At rest PDC in skeletal muscle exists mainly in its phosphorylated (deactivated) state.  At 
the commencement of contraction the initial activation of PDC is thought to be through 
calcium ion stimulation of PDP activation.  This initially crude activation is then further 
µILQH WXQHG¶ E\ WKH DFWLRQ RI VXEVWUDWH DQG SURGXFW IHHGEDFN HJ. [ATP]/[ADP], 
[NADH]/[NAD+] and [acetyl-&R$@>&R$6+@UDWLRV7KLVµILQHWXQLQJ¶LVEHOLHYHGWREH
mediated through the stimulation and inhibition of the PDK isoenzymes, as PDP seems 
relatively insensitive to physiological or pathological disturbances, although there is some 
effect of acetyl-CoA and NADH directly upon the E2 subunit, through reducing the 
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availability of oxidised lipoyl groups on the E2 PDC component.  This would reduce the 
formation of E1-[TPP], leading to a reduction of pyruvate decarboxylation at the rate 
limiting step in the whole PDC reaction (Denton et al, 1975). 
 
3'&¶V UHJXODWRU\ HQ]\PHV 3'. DQG 3'3 DUH FRQVWDQWO\ DFWLYH LQ WKH PLWRFKRQGULD
controlling the amount of phosphorylated, and therefore inactive, PDC through their 
action whilst bound mainly at the E2 subunit lipoyl domains (Figure 1.3). 
 
Pyruvate dehydrogenase phosphatase dephosphorylates the serine residues on the E1 
subunit and actives PDC as a whole.  It is only weakly bound to the E2 hub of the 
enzyme complex (Wieland et al, 1983) and requires the presence of magnesium ions to 
enable tighter binding of the enzyme to the E2 subunit.  PDP activity is reduced in the 
presence of a high [NADH]/[NAD+] ratio, in contrast to PDK.  Two isoenzymes of 
pyruvate dehydrogenase phosphatase (PDP) have so far been identified, both of which 
require magnesium ions for their action.  These also show differences in distribution, 
kinetic parameters and regulation between one another.  PDP1 is found predominantly in 
skeletal muscle mitochondria with an almost undetectable amount present in mammalian 
liver, whilst PDP2 seems to reside in liver and adipocyte mitochondria (Huang B et al, 
1998).    PDP1 needs calcium ions for full activity (as the presence of calcium ions 
promotes the association of PDP with PDC), whilst PDP2, which appears to be calcium 
independent, seems to have a similar activity to a fully activated PDP1.  PDP2 is also 
stimulated by the presence of spermine, and although this is unlikely to be a likely 
stimulus in vivo it does suggest the presence of another regulatory substance. There is 
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some evidence that PDP2 is sensitive to insulin, resulting in stimulation of the pyruvate 
dehydrogenase complex within tissues with a predominantly biosynthetic function 
(Huang et al, 1998).   
 
Pyruvate dehydrogenase kinase (PDK) is tightly bound to the E2 hub of the pyruvate 
dehydrogenase complex (Linn et al, 1969), and inactivates the PDC by phosphorylating 
one or all of three serine residues on the  chain of the E1 component (Serine-264 (site 
1), Serine-271 (site2) and Serine-203 (site3)) (Linn et al, 1969).  Phosphorylation of the 
serine residue at site 1 has been demonstrated to fully inactivate PDC (Sugden et al, 
1979) and it has been suggested that phosphorylation at the other two sites may slow 
reactivation by PDP.  As mentioned above, PDK activation is stimulated by an increase 
in the [acetyl-CoA]/[CoASH] and [NADH]/[NAD+] ratios ensuring that PDC flux is 
reduced when acetyl group availability is high.  PDK activity is reduced by the presence 
of pyruvate, as well as a reduction in the [acetyl-CoA]/[CoASH] and [ADP]/[ATP] ratios.  
Dichloroacetate (discussed later), and other halogenated carboxylic acids (Whitehouse 
and Randle, 1973), also markedly reduce PDK activation through an effect similar to the 
inhibition from pyruvate.   
 
Four discrete PDK isoenzymes have been identified in human skeletal muscle (PDK 1-4) 
(Gudi et al, 1995; Bowker-Kinley et al, 1998) with varying concentrations, specific 
activities and kinetic properties.  As the changes in activation state of PDC appear to 
correlate with changes in PDK activity under a number of circumstances (Hansford et al, 
1976; Cate and Roche, 1978) there has been much interest in these isoforms. 
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Figure 1.3 ± Mechanisms regulating the pyruvate dehydrogenase complex (PDC) by 
phosphorylation-dephosphorylation, together with the reaction catalysed by PDC and its 
links with other metabolic pathways. 
 
Key: 
PDK  Pyruvate dehydrogenase kinase. 
PDP  Pyruvate dehydrogenase phosphatase. 
TCA  Tricarboxylic acid cycle. 
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The commonest isoforms identified in skeletal muscle are PDK2 and 4, thought to be 
responsible for the inactivation of PDC in response to alterations in pyruvate and lipid 
availability respectively.  The distribution of the four PDK isoforms between tissues 
suggests that there exists a need for a differing activation of PDC between these tissues.   
 
PDK1 has been demonstrated to mainly reside in human heart tissue, with low levels of 
expression in skeletal muscle (Popov et al, 1994).  The functional role of PDK 1 is 
currently unclear, but Bowker-Kinley et al (1998) have suggested that it may be 
responsible for detecting changes in the concentrations of intra-mitochondrial pyruvate 
and ADP in the heart. 
PDK2 mRNA has been found to be highly expressed in most human tissues (Popov et al, 
1994).  It is the most sensitive isoenzyme to ATP and also the most sensitive to inhibition 
by dichloroacetate (Bowker-Kinley et al, 1998).  It has been suggested, by the same 
group, that PDK2 is the major PDK isoform involved in control of mammalian PDC 
activity, due to its profuse expression within most tissues. 
PDK3 is mostly found in testes, and possesses the highest specific activity of all the PDK 
isoforms (1250 nmol.min-1.mg; Bowker-Kinley et al, 1998).  It has been suggested to 
have a specific role within the testes, although that has not yet been clarified. 
PDK4 is mostly found within cardiac and skeletal muscle and is relatively insensitive to 
changes in [ADP], [ATP], the [NADH]/[NAD+] ratio and acetyl-CoA concentration 
(Bowker-Kinley et al, 1998).   Due to its relative insensitivity to the presence of pyruvate, 
it allows for the inhibition of PDC action without a reduction in the concentration of 
pyruvate required for other processes, such as transamination to alanine prior to 
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metabolism in situations of chronic negative nitrogen balance.  PDK4 seems to possess 
more of a role in the long term regulation of PDC activation within skeletal muscle, 
which is supported by the finding in healthy human volunteers fed a high fat/low 
carbohydrate diet an increase in PDK4 mRNA expression was found (Peters et al, 2001) 
and this may be responsible for the suppression of carbohydrate utilisation observed in a 
similar population (Putman et al, 1993).  These findings are supported by findings in the 
rat model that the PDK4 mRNA expressed in heart and skeletal muscle is selectively 
upregulated by starvation, insulin resistance, diabetes mellitus and hyperthyroidism 
(Huang et al, 2002; Wu et al, 1999; Sugden et al, 1998).   
 
Further work (Peters et al, 2001) investigating the effect of high and low carbohydrate 
diets administered to glycogen depleted individuals noted a significant reduction in 
PDK4 mRNA abundance following the high carbohydrate diet (0.068±0.025 with low 
carbohydrate versus 0.021±0.007 after high carbohydrate feeding).  This evidence 
supports the previous work in demonstrating an increase in PDK4 activation in response 
to low carbohydrate stores.  It is uncertain if this response is a result of an increase in 
circulating fatty acid concentrations, or as a response to the reduction of glycogen stored 
within the muscle fibre. 
 
Another hypothesis states that the reduction in plasma insulin concentration seen after 
high fat (73%)/low carbohydrate (5%) feeding exerts an influence over PDK4 activity.  
Following three days of this diet the change in PDK activity was found to be proportional 
WR WKH VXEMHFW¶V QRUPDO OHYHO RI SK\VLFDO DFWLYLW\ 3HWHUV et al, 2001).  As the skeletal 
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muscle of trained individuals is more sensitive to the effects of insulin, it may be that the 
larger increase in PDK4 activity seen is a reflection of this effect.   
 
Similar effects are seen with insulin resistance, and the resultant reduced availability of 
carbohydrate for skeletal muscle metabolism.  This up-regulation of PDK isoforms, 
specifically PDK4, arises in part due to activation of peroxisome-proliferator-activated 
receptor  (PPAR ).  PPAR  is activated by non-esterified fatty acids (NEFA) and is 
likely to account for their inhibitory action upon PDC activation, likely through the 
stimulation of PDK4 activity (Pilegaard and Neufer, 2004).  Peroxisome-proliferator-
activated receptor (PPARs) and FOXO1 are the molecular signalling pathways that have 
been suggested to be involved with the expression of PDK4 mRNA (Wu et al, 2001; 
Degenhardt et al, 2007) or PDK4 protein in skeletal muscle (Constantin et al, 2007).  
 
PPAR  expression increases with aerobic training in both men (Russell et al, 2003) and 
women (Horowitz et al, 2000).  As well as influencing the rate of carbohydrate oxidation 
in skeletal muscle, PPAR  regulates the expression of genes coding for muscle enzymes 
involved in fat metabolism.  The increased PPAR  activity seen with aerobic training 
therefore accounts for the increased potential for fat oxidation, and relative contribution 
from this source during sub-maximal exercise, seen in the skeletal muscle of trained 
subjects. 
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Metabolic inertia at the onset of skeletal muscle contraction. 
PDC activity is low in resting muscle, to prevent the use of carbohydrate stores during 
time of low muscle ATP demand, but is required to increase rapidly at the onset of 
contraction.  However the increase in mitochondrial ATP re-synthesis follows an 
exponential increase (Tschakovsky and Hughson, 1999), within which period the 
increased requirements for ATP regeneration is met via oxygen independent routes.  
During the first 30 seconds of single leg extension exercise at 65 W Bangsbo et al (1990) 
noted that the contribution to ATP generation from glycolysis and phosphocreatine 
breakdown accounted for 80% of total ATP generation.  This proportion decreased to 
45% during the following 60-90 seconds and then 30 % after 120 seconds of exercise and 
appeared to be mirrored by an increase in the contribution from mitochondrial ATP 
generation.  The delay in mitochondrial ATP regeneration has classically been attributed 
to a corresponding delay in skeletal muscle blood flow and therefore oxygen delivery to 
contracting muscle fibres (Richardson et al, 1995).  The increases in skeletal muscle 
oxygen utilisation correspond to the increase in total limb blood flow during the early 
stages of the rest-to-ZRUNWUDQVLWLRQDQGWKHWHUPµR[\JHQGHILFLW¶ZDVXVHGWRGHVFULEH
this phenomenon.  Following the work of Grassi et al (1998a; b), who demonstrated that 
abolishing the delay in muscle blood flow at the onset of exercise did not alter limit the 
rate of oxygen consumption at this time, the conclusion of the authors was that the delay 
arose due to an inertia in microvascular oxygen delivery or mitochondrial energy 
provision.  
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The pyruvate dehydrogenase complex as the location for this delay in mitochondrial ATP 
regeneration has been the focus of research within the School of Biomedical Sciences 
over the last 10 years, with the demonstration in 1996 of PDC activation by DCA leading 
to a reduction in both phosphocreatine hydrolysis and lactate accumulation during intense 
exercise with the blood flow (and oxygen delivery) fixed at near resting levels (Timmons 
et al, 1996).  Further work exploring this finding in both human and canine skeletal 
muscle demonstrated that the phosphocreatine hydrolysis and lactate accumulation were, 
in part, due to a delay in the provision of oxygen-dependent ATP regeneration at the 
commencement of contraction (Timmons et al, 1997; 1998b).  The same investigators 
demonstrated that DCA infusion lead to an increase in the pool of acetyl groups available 
for entry into the TCA cycle during contraction.  From this evidence it was concluded 
that activation of, and corresponding flux through, PDC is limiting to acetyl-CoA 
availability and mitochondrial ATP re-synthesis at the onset of exercise.  Pre-treatment 
with DCA, and the resultant accumulation of acetyl groups prior to exercise, could 
increase the overall contribution of oxidative pathways to total ATP production at the 
onset of exercise. 
 
Research has demonstrated the accumulation of acetyl groups during moderate to intense 
contraction (Harris et al, 1987; Howlett et al, 1999b) in contradiction to the suggestion 
that the inertia during the rest-to-work period is due to an inadequacy of the supply of 
acetyl-CoA via PDC to meet the demands of contraction.  However these investigators 
had not investigated the metabolic changes occurring during the initial stages of 
contraction, and work by Roberts et al (2002a) was able to demonstrate the existence of a 
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period of metabolic inertia in skeletal muscle at the onset of contraction using a canine 
model of ischaemic contraction in which five muscle biopsies were obtained during the 
first minute of contraction.  These results demonstrated a delay in acetyl group provision 
that was mirrored by, and resulted from, a delay in PDC activation during the initial 20 
seconds of contraction. 
 
From this research using DCA, which both activates PDC and acetylates the free 
coenzyme A and acetylcarnitine pools at rest, it was not possible to determine if the 
location of the inertia was in acetyl-CoA delivery via PDC at the onset of contraction or 
due to an increase in the pool of acetyl groups available to enter the TCA cycle.  Further 
research (Roberts et al, 2001; Evans et al, 2001), using acetate infusions to increase the 
provision of acetyl groups without activation of PDC, demonstrated that there was no 
alteration in oxidative phosphorylation following acetate pre-treatment.  Further, Roberts 
et al (2001) demonstrated that it was acetyl-CoA derived from PDC, rather than the 
pooled acetyl groups prior to the onset of contraction, which provided the principal route 
of substrate entry into the TCA cycle.  This research has suggested that the site of 
metabolic inertia at the onset of skeletal muscle contraction is at the level of the pyruvate 
dehydrogenase complex.   
 
The contribution of mitochondrial ATP regeneration, and therefore the degree of 
metabolic inertia subject to modification by DCA pre-treatment, is dependent on the 
intensity of exercise (the rate of ATP degradation and therefore the rate of accumulation 
of ADP and AMP, which activate phosphocreatine degradation and glycolysis) and the 
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time taken to achieve a steady state of energy provision and utilisation (Hultman et al, 
1967; Howlett et al, 1998).  This, as discussed above, may explain the upper threshold of 
efficacy from DCA pre-treatment in overcoming metabolic inertia present at the rest-to-
work transition. 
 
µ3ULPLQJ¶RIVNHOHWDOPXVFOHWKDWLVLQFUHDVLQJWKHDYDLODELOLW\RIDFHW\OJURXSVIRUHQWU\
into the TCA cycle, can also be achieved by an initial period of low intensity exercise.  A 
ten minute bout of exercise at 55% VO2max doubled the skeletal muscle acetylcarnitine 
concentration and trebled the muscle lactate concentration when compared to resting 
values (Campbell-2¶6XOOLYDQ et al, 2002).  When a subsequent ten minute bout of 
exercise at 75% VO2max was performed there was no difference noted at the end of the 
bout of exercise in the concentrations of metabolites or the contribution from non-oxygen 
dependent ATP resynthesis between either the group that had performed an initial low 
LQWHQVLW\µZDUPXS¶Eout and a matched control group.  However during the first minute 
of exercise there was significant sparing of PCr and a reduction in the formation of 
lactate and glucose-6-phosphate (G-6-3 LQ WKH JURXS WKDWKDGSHUIRUPHGD µZDUPXS¶
This group had a markedly reduced contribution to ATP resynthesis from non-oxygen 
dependent routes (reduced by approximately 45%) which demonstrates an attenuation of 
the inertia normally present at the onset of contraction in skeletal muscle.   
 
Role of carnitine and influence of exercise intensity on fuel selection. 
Carnitine plays an integral role in normal cellular metabolism, being required for the 
optimal utilisation of fuel substrates by skeletal muscle during exercise through two vital 
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roles (Brass and Hiatt, 1994).  The entry of cytosolic long-chain acyl-CoA into the 
PLWRFKRQGULRQIRUPLWRFKRQGULDOȕ-oxidation is dependent on the formation of long chain 
acylcarnitines through the action of carnitine palmitoyltransferase 1 (CPT1) (Murthy and 
Pande, 1987).  The long-chain acylcarnitine so formed is then exchanged with free 
intramitochondrial carnitine via carnitine acylcarnitine translocase where carnitine 
palmitoyltransferase 2 (CPT2) catalyses the transesterification back to acyl-CoA and free 
carnitine.  The acyl-CoA mD\WKHQHQWHUWKHȕ-oxidation pathway to form acetyl-CoA for 
further metabolism.   
 
Carnitine metabolism varies in relation to the metabolic state of the cell.  At rest 80% of 
the total muscle carnitine pool is present as carnitine, 15% as short-chain acylcarnitines 
and 5% as long-chain acylcarnitines.  Within 10 minutes of high-intensity exercise (75% 
VO2max) the muscle carnitine pool is predominantly (45-75%) short-chain 
acylcarnitines, primarily acetylcarnitine, with only 20% remaining as carnitine (Harris et 
al, 1987).  The concentration of skeletal muscle acetylcarnitine has been demonstrated to 
correlate with both muscle lactate concentration (Sahlin, 1990) and muscle acetyl-CoA 
content (Carlin et al, 1990; Constantin-Teodosiu et al, 1991b) further indicating its link 
to the metabolic state of the muscle.  This correlation between acetylcarnitine 
concentration and muscle acetyl-CoA content is believed to occur due to buffering of 
acetyl groups generated by the action of PDC that are in excess of those required for 
utilisation by the TCA cycle enabling an adequate supply of fee CoASH for use in PDC 
and TCA cycle reactions.  In support of this suggestion is the finding that there is no 
change in muscle acetylcarnitine content during exercise at lower (30-40% VO2max) 
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intensity when the rate of acetyl-CoA formation from both pyruvate and fatty acid 
metabolism is better matched to the demand from the TCA cycle (Sahlin, 1990).  In 
addition to buffering acetyl groups in this manner, this store of acetyl groups is also 
available for transacetylation back to acetyl-CoA for further metabolism. 
 
The relative utilization of fat or carbohydrate fuel during exercise is strongly dependent 
on exercise intensity.  The mechanisms by which this regulation occurs are not fully 
XQGHUVWRRG ZLWK WKH µ*OXFRVH-))$ F\FOH¶ 5DQGOH et al, 1963) being suggested as an 
explanation for the reduction in muscle carbohydrate oxidation rate in the presence of 
high plasma FFA concentration.  It was proposed that an increase in the mitochondrial 
acetyl-CoA/CoA ration would suppress PDC activation during exercise, therefore 
reducing carbohydrate oxidation and stimulating fat oxidation.  However studies have 
since demonstrated no limitation of fat oxidation during high-intensity exerFLVH 
VO2max) in association with changes of plasma FFA availability (Dyck et al, 1993; 
Romijn et al, 1995).   
 
There is growing evidence to suggest that flux through PDC may indirectly regulate fatty 
acid oxidation during exercise, through the observation that increasing glucose 
availability prior to exercise at 50% VO2max reduced the oxidation of long-chain fatty 
acid with a reduction in muscle long-chain acylcarnitine content (Coyle et al, 1997).  This 
reduction persisted after restoration of plasma FFA concentrations (via the administration 
of lipid and heparin infusions) suggesting that the effect of increasing carbohydrate 
availability is not dependent on changes in FFA availability (Horowitz et al, 1997).  In 
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support of this suggestion the increase in PDC flux seen with increased exercise intensity 
or increases in carbohydrate availability during exercise is associated with a 
corresponding decrease in long-chain fatty acid oxidation rates (van Loon et al, 2001; 
Roepstorff et al, 2005).   
 
There have been two suggested mechanism through which this inhibition has been 
suggested to occur, via the inhibition of CPT1 activity by malonyl-CoA and the influence 
of PDC flux on free carnitine activity.  Skeletal muscle malonyl-CoA is synthesised from 
acetyl-CoA via the action of acetyl-CoA carboxylase, an enzyme which is increasingly 
activated by an increase in the cytosolic concentration of citrate (Saha et al, 1995).  In the 
presence of increased glycolytic flux, the concentrations of both citrate and acetyl-CoA 
are increased leading to a corresponding increase in the muscle malonyl-CoA 
concentration.  Malonyl-CoA in known to be a potent inhibitor of CPT1 activity in vitro 
and changes in its concentration in resting human skeletal muscle have occurred with 
inverse changes in fat oxidation (Bavenholm et al, 2000).  However it appears that this 
finding is not supported during exercise as studies demonstrate no association between fat 
oxidation rates and malonyl-CoA concentrations during prolonged moderate intensity 
(40% followed by 65% VO2max) exercise (Odland et al, 1996) or exercise at 
65%VO2max in glycogen depleted individuals (Constantin-Teodosiu et al, 1991b).  As 
carnitine is the principal substrate for CPT1, the decreases in concentration seen during 
high-intensity exercise may limit the ability of CPT1 to transport long-chain acyl-CoA 
LQWRWKHPLWRFKRQGULDOPDWUL[IRUȕ-oxidation (Stephens et al, 2006), a finding supported 
by the finding of van Loon et al (2001) that there is a 35% decrease in the rate of long-
 41 
chain fatty acid oxidation during exercise at an intensity above 75% VO2max (Fig 1.4).  
Achten and Jeukendrup (2004) demonstrated that during exercise maximum and 
minimum fat oxidation rates are obtained at intensities of approximately 65% and over 
80% VO2max respectively, when free carnitine content has been demonstrated to 
decrease from approximately 11 mmol.(kg dm)-1 at 60% VO2max to below 5.5 mmol.(kg 
dm)-1 at an exercise intensity of approximately 80% VO2max. 
 
The causes of fatigue during exercise depend upon the intensity and duration of exercise 
performed.  During short duration, high-intensity (above 90% VO2max) exercise 
phosphocreatine depletion leads to skeletal muscle fatigue.  The accumulation of 
metabolic by-products (especially lactate) also result in a lowering of muscle pH, which 
both reduces the rate of glycolysis (in turn reducing the generation of ATP for continued 
contraction) and affects the binding of calcium ions to troponin.  Prolonged exercise 
instead relies upon glycogen (both within the contracting muscle and also stores present 
within the liver) for continued generation of energy for contraction.  As muscle glycogen 
is consumed there is a corresponding increased reliance on blood glucose to provide 
carbohydrate for muscle contraction.  A fall in blood glucose will result in increased rates 
of liver glycogenolysis in an attempt to maintain the blood glucose concentration.  When 
the rate of liver glycogenolysis is less than the rate of muscle glucose uptake then the 
blood glucose concentration and carbohydrate provision for continued contraction will 
become limited, leading to fatigue. 
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Figure 1.4 Contribution of substrates to total energy expenditure during cycling 
exercise at 40, 55 and 75% Wmax.  From van Loon et al (2001), modified. 
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The effect of dietary changes on PDC activation. 
Lowering the availability of carbohydrate as a fuel for contracting muscle (whether 
through the administration of high-fat, low carbohydrate diet, or starvation) results in a 
reduction of PDC activation at rest and the rate of activation during exercise at 75% 
VO2max.  A comparison (Putman et al, 1993) between subjects cycling at 75% VO2max 
after consumption of a low (3% carbohydrate, 51% fat and 46% protein) carbohydrate 
diet also demonstrated  
 a reduction in VCO2 and RQ  
 reduced blood lactate concentration during exercise 
 reduced muscle glycogen content 
 reduced muscle pyruvate and lactate concentration 
when compared to the same population after consumption of a high (86% carbohydrate, 
4% fat and 10% protein) carbohydrate diet.  All of these findings demonstrate a reduction 
in carbohydrate metabolism during exercise, as an attempt to preserve carbohydrate 
stores.  Stellingwerff et al (2002) were able to demonstrate that reducing fatty acid 
availability stimulated carbohydrate oxidation in skeletal muscle during moderate 
intensity exercise (70% VO2max).  This was suggested to occur due to a reduction in the 
[NADH]/[NAD+] ratio prior to contraction, which would inhibit PDK activity and 
therefore increase resting PDC activation. 
 
Aerobic training, and its increased ability to utilise fatty acids as a fuel source during 
contraction, are of particular relevance when we consider the skeletal muscle of patients 
with the metabolic syndrome.  This syndrome consists of impaired glucose tolerance, 
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insulin resistance and mild to severe lipid abnormalities and is a risk factor for the 
development of cardiovascular disease as well as a common co-morbidity of patients with 
PAD (Gorter et al, 2004; Olijhoek et al, 2004).  Nine months of aerobic training in these 
patients induced key proteins involved in glycolytic and oxidative metabolism (PDH -1 
subunit, LDH and glutamate-oxoglutarate transaminase (GOT1))(Hittel et al, 2005) 
allowing for improved integration of the glycolysis and the TCA cycle within skeletal 
muscle.  This beneficial response to aerobic training was preserved or even exaggerated 
in patients with the metabolic syndrome, but these benefits were lost within a two week 
period of de-training highlighting the requirement for regular exercise therapy in the 
treatment of this condition.   
 
Alterations in the balance between carbohydrate and fat metabolism in non-contracting 
skeletal muscle are inherently linked to the activation of PDC.  Low carbohydrate feeding 
will result in an increase in PDK activity in an attempt to preserve carbohydrate stores 
from their irreversible metabolism through PDC (Peters et al, 2001).  Interaction of the 
regulatory pathways controlling carbohydrate and fatty acid oxidation allows control of  
their respective activities.  Metabolites and co-factors for each pathway exert regulatory 
effects upon enzymes such as PDC and carnitine palmitoyltransferase (CPT) so that 
fluctuations in the substrate available for metabolism are adjusted to within the 
mitochondrion.  Again alterations in the both the action of PDK and its sensitivity to its 
normal regulatory factors, especially pyruvate, regulate many of these changes (Spriet et 
al, 2004; Sugden and Holness, 2003).  Starvation desensitises PDK to the inhibitory 
effects of pyruvate, in order to preserve carbohydrate stores.  Exposure to fatty acids will 
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also stimulate PDK4 activity and alter the NADH/NAD+ ratio and intramitochondrial 
concentration of acetyl-CoA, further inhibiting PDC and ensuring preservation of 
carbohydrate. 
 
The role of PDC activation in the balance between carbohydrate and fatty acid oxidation 
during steady state contraction does not seem to be the same as that found in non-
contracting muscle.  The glucose-fatty acid cycle (GFC) which links the concentrations 
of NEFA to the rate of carbohydrate oxidation seems not to operate during submaximal 
steady state skeletal muscle contraction.  After the administration of nicotinate, which 
limits NEFA availability to contracting muscle via its inhibition of hormone-sensitive 
lipolysis, to dogs the measured PDC activation during steady state contraction decreased 
(Timmons et al, 1998c).  Had lipid and carbohydrate oxidation been linked, then a rise in 
PDC activity would be expected, and the above findings suggest that an alternative 
mechanism exists for the regulation of these processes in contracting skeletal muscle. 
 
Sodium dichloroacetate. 
Sodium dichloroacetate (DCA) is a systemic activator of PDC (Whitehouse and Randle, 
1973), having its effects by indirectly inhibiting PDK and therefore increasing the 
amount of PDC in its phosphorylated, and therefore active, form.  It is similar in structure 
to pyruvate, which is thought to account both for its ability to enter the mitochondria 
(Halestrap, 1975) and its action upon PDK.   
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As stated above, whilst DCA inhibits all of the PDK isoforms it has its greatest effect 
upon PDK2, resulting in a greater proportion of PDC in most tissues remaining in its 
active form.  Administration of DCA has been demonstrated to result in the acetylation of 
the free carnitine and coenzyme-A pools at rest to a level seen at maximal exercise 
(Howlett et al, 1999b), as well as increasing the flow of pyruvate through PDC enabling 
an increase in the regeneration of ATP via oxygen dependent pathways.  These effects 
led to a reduction in phosphocreatine breakdown, glycogenolysis and the accumulation of 
both Pi and lactate during the initial 2 minutes of exercise (Howlett et al, 1999b).  The 
activity of DCA is most noticeable during the initial 20 seconds of contraction when 
inertia at this level is thought to exist due to mitochondrial enzyme delays (Greenhaff et 
al, 2002).  Once this inertia has been overcome (so that PDC activation has reached 
levels adequate to meet the metabolic demands of the contracting muscle) the effect of 
DCA is minimal.  This may explain why a reduced effect of DCA upon skeletal muscle 
metabolism during higher intensity exercise (>90% VO2max) is seen (Howlett et al, 
1999a), as the exercise related activation of PDC is able to match the increased activation 
from DCA administration.  As such activation of PDC and the increased production of 
ATP via oxidative mechanisms, which are more efficient but slower in their delivery, is 
likely to have a reduced effect at these high intensities.  During exercise at and above 
maximal intensity the delayed respiratory response has been suggested to be located at 
some point within the TCA cycle or electron transfer chain (Howlett et al, 1999a; 1999b) 
due to the lack of a significant effect of DCA pre-treatment.    
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Using the same isolated in-situ dog gastrocnemius model as their previous experiments 
investigating the effects of changes in conductive and diffusive O2 upon VO2 on-kinetics 
Grassi et al (2002) were able to demonstrate a significant preservation of the mean 
fatigue index (average values of force determined every 10 seconds/initial force; 0.73± 
0.03 vs. 0.81 ±0.05, CON vs. DCA, p=0.02) from 80 seconds until the end (240 seconds) 
of exercise at approximately 70% VO2max after the administration of DCA (300mg.(kg 
body mass)-1), as well as a ~30% reduction in both PCr degradation during exercise and 
final muscle lactate concentration.  Whilst this model failed to demonstrate the PDC as 
the site of metabolic inertia, the authors accepted that this model had some limitations in 
this respect.  After DCA administration the metabolic efficiency of the muscle was 
increased leading to an increased force generation.  The effect observed on the 
contribution to ATP resynthesis from oxygen-independent sources was less pronounced 
than previously observed in similar experiments, although the authors mentioned that a 
variation in muscle fibres between species may account for some of this effect (as dog 
gastrocnemius consists of a much higher proportion of type Ia muscle fibres when 
compared to human skeletal muscle).  
 
It might be expected that when the metabolic inertia during the rest-to-work transition is 
prolonged, such as in patients with peripheral vascular disease (PVD) (Greenhaff et al, 
2004), that DCA would exert a longer influence over mitochondrial ATP provision.  In 
keeping with this suggestion research (Parolin et al, 2000; Timmons et al, 1998b) has 
demonstrated a prolonged effect of DCA pre-treatment on glycogenolysis and ATP 
provision in healthy volunteers exercising during hypoxia.  Parolin et al (2000) were able 
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to demonstrate that the administration of 100 mg.(kg body weight)-1 DCA to healthy 
subjects exercising in hypoxic conditions reduced the contribution of substrate level 
phosphorylation (phosphocreatine (PCr) breakdown and glycogenolysis) to ATP 
regeneration.  DCA pre-treatment directed 83% of PDC flux during the first minute of 
exercise to oxidative mechanisms, as compared with 56% of flux under hypoxia with a 
control infusion.  This difference occurred due to a reduction in flow towards 
acetylcarnitine formation during the rest-to-work transition in those subjects pre-treated 
with DCA, as a large pool of acetyl groups already exists available for entry into the TCA 
F\FOH7KLVEHWWHU³PDWFKLQJ´RI$73SURYLVLRQDQGGHPDQGVUHVXOWHGLQSUHVHUYDWLRQRI
muscle glycogen and PCr, and a reduction therefore in the generation of lactate and Pi.  
Other research has demonstrated a 50% reduction in both PCr degradation and muscle 
lactate accumulation during the first three minutes of ischaemic exercise at ~65% 
VO2max in human volunteers (Timmons et al, 1998b) and a ~15% less reduction in 
isometric muscle tension as well as an 83% reduction in muscle lactate and 54% 
reduction in PCr hydrolysis in a canine model of partial ischaemia (Timmons et al, 1996) 
following the administration of DCA (50mg.(kg body mass)-1 (Timmons et al, 1998b); 
300mg.(kg body mass)-1 (Timmons et al, 1996)).  Recent researchers (Calvert et al, 2008) 
have also indicated a similar effect of DCA pre-treatment in patients with impaired 
skeletal muscle function secondary to chronic obstructive pulmonary disease (COPD), 
where a 20% reduction in peak blood lactate concentration and 15% reduction in peak 
blood ammonia was associated with a significant increase in mean peak exercise 
workload during symptom-limited maximal intensity cycling exercise. 
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In sepsis, which increases the flux through glycolysis, the most frequently observed 
metabolic disturbanFH LV DQ LQFUHDVHG EORRG ODFWDWH FRQFHQWUDWLRQ /¶+HU DQG 6HEHUW
2001) although the exact mechanism by which this arises is unclear.  DCA administration 
(20mg.(100g body mass)-1) in a rat model of sepsis resulted in a ~25% reduced 
concentration of muscle lactate after four hours, suggesting that PDC activity may also be 
UHGXFHG GXULQJ VHSVLV /¶+HU DQG 6HEHUW   7KLV ZRXOG VXSSRUW WKH ILQGLQJV RI
increased PDK activation in states of negative nitrogen balance, such as sepsis, 
mentioned above (Vary, 1991; Sugden et al, 2000).   
 
Administration of DCA in an animal model of ischaemia/reperfusion (Wilson et al, 2003) 
reduced the blood lactate concentration and the rise in end-tidal CO2 measured 15 
minutes after reperfusion following four hours of ischaemia.  These investigators also 
noted a reduced percentage of animals having more than 10% skeletal muscle necrosis 
within sections of the anterior tibialis muscle following iliac artery occlusion in the group 
receiving DCA treatment.  The hypothesis suggested by this group was that activation of 
PDC resulted in provision of acetyl-CoA from pyruvate for entry into the TCA cycle, and 
subsequent ATP production, even at low muscle oxygen tensions.  As a mechanism for 
the avoidance of reperfusion metabolic acidosis and its associated morbidity and 
mortality in acute limb ischaemia, or the activation of the inflammatory cascade and the 
systemic inflammatory response syndrome (SIRS) from intermittent episodes of 
ischaemia and reperfusion (as seen in patients with intermittent claudication), the PDC is 
a promising therapeutic target of likely clinical benefit.  Prevention of ischaemia-
reperfusion endothelial injury in patients with intermittent claudication could avoid the 
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development of accelerated atherosclerosis and other systemic manifestations of chronic 
inflammation, which would be of benefit to this population. 
 
Therapeutic PDC activation has been suggested as a means of reducing hyperglycaemia 
in patients with diabetes mellitus (Stacpoole and Felts, 1970), hyperlactataemia in 
conditions of both lactic acidosis (Stacpoole et al, 2006; Barshop et al, 2004) and 
ischaemia-reperfusion, such as that seen with peripheral vascular disease (Greenhaff et 
al, 2004; Wilson et al, 2003).  The use of DCA as a therapeutic tool is limited by its 
toxicity after chronic administration, which has been demonstrated in both animals (Katz 
et al, 1981) and humans (Stacpoole et al, 1979) at a range of doses.  The results of these 
studies have linked chronic administration of DCA with reversible neuropathies in human 
volunteers (Stacpoole, 1989) and with a wide variety of effects (including dyspnoea, 
pneumonia, conjunctivitis, diarrhoea and death) in animals (Cicmanec et al, 1991).  Some 
of these effects are thought to be due to depletion of body thiamine stores (Stacpoole et 
al, 1990), which is a co-factor for both PDC and the ketoglutarate dehydrogenase 
complex that DCA activates.  Whilst there have been attempts to manufacture a 
combined thiamine-dichloroacetate treatment (Henderson et al, 1994), it remains unclear 
if this will avoid the toxic effects described above. 
 
Forkhead box O transcription factors. 
The Forkhead box O (FOXO) class of transcription factors are believed to be a central 
metabolic regulator in glucose and lipid metabolism, as many signalling pathways 
converge on these factors (especially FOXO1).  FOXO1 both induces or represses the 
 51 
expression of many target genes involved in metabolism within insulin-responsive tissue 
and performs transcriptional control on signalling molecules. 
 
FOXOs are highly expressed in both white and brown adipose tissue (Nakae et al, 2003) 
and their expression levels are altered by high fat feeding (Nakae et al, 2008).   
5HVHDUFKHUV KDYH VXJJHVWHG WKDW )2;2 PD\ VXSSUHVV 33$5Ȗ H[SUHVVLRQ DW WKH
transcriptional level.  Dowell et al (2003) described the finding that FOXO1 decreased 
WKH IRUPDWLRQ RI D 33$5Ȗ5[U'1$ FRPSOH[  )XUWKHUPRUH LW KDV DOVR EHHQ UHSRUWHG
(Armoni et al  WKDW )2;2 FDQ DOVR LQKLELW 33$5Ȗ DQG 33$5Ȗ SURPRWHU
activity throXJKGLUHFWLQWHUDFWLRQEHWZHHQ)2;2DQG33$5ȖSURPRWHU 
 
In Drosophilia during the nutrition-limited state FOXO enhances both transcription of 
LQVXOLQ UHFHSWRU ³SULPHV IRU FKDQJHV LQ QXWULHQW DYDLODELOLW\´ DQG H[SUHVVLRQ RI WKH
translational expressor 4ebp, which inhibits growth (and therefore spares nutrients which 
can then be directed towards storage).  FOXO1 induces expression of Irs2 which may 
improve insulin sensitivity in the insulin resistant state. 
 
FOXOs are expressed in skeletal muscle at a level that is adjusted to changes in energy 
metabolism.  In skeletal muscle the binding of insulin activates two signalling pathways: 
the Ras-Raf-MEK-ERK pathway (which does not influence muscle fibre size - Murgia et 
al, 2000) and the PI3K/AKT pathway.  Activation of the PI3K/AKT pathway appears to 
stimulate muscle hypertrophy through stimulation of translation via regulation of GSK 
and mTOR kinases (Bodine et al, 2001).  mTOR is also regulated by the supply of amino 
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acids and glucose to the muscle (Kim et al, 2003) enabling it to integrate signals from 
PI3K/AKT pathway with the nutritional status of the cell.  One of the downstream targets 
of the PI3K/AKT pathway is the Forkhead box O (FOXO) class of transcription factors, 
of which three are found in mammalian cells (FOXO1, FOXO3 and FOXO4 (Tran et al, 
2003)).  Researchers (Brunet et al, 1999) have demonstrated that AKT blocks the 
function of all three FOXO factors by phosphorylation.  FOXO factors are required for 
the development of insulin resistance in type II diabetes (Nakae et al, 2002) as well as 
being induced during starvation.  Expression of FOXO1 and FOXO3a was increased in 
starvation and after glucocorticoid treatment (Furuyama et al, 2003).  Activation of 
FOXO factors leads to muscle fibre atrophy through its relation with MAFbx (muscle 
atrophy F box, Atrogin 1) and MuRF1 (muscle RING finger 1) which conjugate ubiquitin 
to protein substrates.  During atrophy FOXO1 and FOXO3a expression is increased.  A 
skeletal muscle specific FOXO1 transgenic mouse showed reduced body weight due to a 
reduction in lean body mass (Kamei et al, 2004).  These mice showed poor glycaemic 
control and reduced exercise tolerance. 
 
Starvation reduces blood glucose and insulin concentrations, decreases insulin¶V actions 
and results in the nuclear accumulation of FOXO factors.  FOXO factors can accelerate 
glucose production, reduce insulin secretion, decrease fat and muscle mass and generate 
spare energy in vivo.  In humans in an insulin resistant state, such as after excessive 
caloric intake, the FOXO factors are active even when not in a calorie restricted state.  In 
these circumstances this increased activity may lead to accelerated insulin resistance, 
eventually resulting in type 2 diabetes mellitus and hyperlipidaemia.   
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Muscle atrophy occurs in response to disuse, fasting and as a response to various diseases 
(cancer, AIDS, diabetes mellitus).  Regardless of the causative factor these muscles show 
increased rates of protein degradation through activation of the ubiquitin-proteasome 
pathway (Jagoe and Goldberg, 2001).  Atrophy induces the protein atrogin-1 (MAFbx) 
most dramatically (mRNA increased 8-40 fold in all types of atrophy) and this increase 
precedes muscle weight loss.  Although low concentrations of insulin can trigger muscle 
protein loss in diabetes and starvation (Mitch et al, 1999) the signal pathway by which 
this is achieved was unclear until recently.   
 
Sandri et al (2004) have demonstrated both atrophy of myotubes and mature muscle 
fibres by FOXO stimulation and a reduction in the induction of atrogin-1 by fasting after 
inhibition of FOXO function.  These authors suggested that FOXO factors stimulated 
many atrophy related genes and enhanced protein degradation, most likely through 
transcription of the gene for MuRF-1.  In conditions of reduced insulin concentration or 
resistance to its effects AKT is dephosphorylated, resulting in activation FOXO and 
therefore transcription of atrogin-1, MuRF-1 and other genes that promote muscle 
wasting.  These changes reduce protein synthesis through the dephosphorylation of 
mTOR, GSK and S6K resulting in a reduction in cell protein and myofibre size.   
 
Peroxisome proliferator-activated receptors.  
Peroxisome proliferator-activated receptors (PPARs) belong to the 
steroid/thyroid/retinoid superfamily and are nuclear lipid-activable receptors that control 
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a number of genes in several pathways of lipid metabolism.  These pathways include 
IDWW\ DFLG WUDQVSRUW DQG XSWDNH LQWUDFHOOXODU ELQGLQJ DQG DFWLYDWLRQ FDWDEROLVP E\ ȕ- 
oxidatiRQ DQG Ȧ-oxidation) or storage.  PPARs possess the classic domain structure of 
other nuclear receptors (e.g. steroid or thyroid hormone receptors) (Ferré, 2004) with an 
NH2-terminal region with a ligand-independent transactivation domain (AF-1), followed 
by a DNA-binding domain and a ligand and dimerization domain and a ligand-
independent activation domain (AF-2) at the COOH-terminus.  The PPARs bind to the 
peroxisome proliferator response element on the DNA as obligate heterodimers with the 
9-cis-retinoic acid receptor (RXR) (Desvergne and Wahli, 1999). 
 
Three related PPAR isotypes 33$5Į 33$5ȕį DQG 33$5Ȗ KDYH EHHQ LGHQWLILHG LQ
humans (Dreyer et al, 1992; Schmidt et al, 1992). 
 
 33$5Į 
Data from research performed in human subjects LQGLFDWH WKDW 33$5Į LV IRXQG
predominantly in the liver, but also in heart, kidney, skeletal muscle and large intestine 
(Mukherjee et al, 1997; Auboeuf et al   7KH H[SUHVVLRQ RI 33$5Į DSSHDUV WR
FRUUHODWH ZLWK KLJK PLWRFKRQGULDO DQG SHUR[LVRPDO ȕ-oxidation activities, such as in 
cardiac muscle and the cells of the kidney proximal tubule (Desvergne and Wahli, 1999). 
 
33$5ĮELQGVXQVDWXUDWHGIDWW\DFLGVDWDKLJKHUDIILQLW\WKDQWKHRWKHULVRIRUPVZLWKD
ORZHU DIILQLW\ IRU VDWXUDWHG IDWW\ DFLGV  ,Q WKH OLYHU DFWLYDWLRQ RI 33$5Į LQGXFHV WKH
expression of fatty acid transport proteins and long-chain acyl-CoA synthetase 
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(Schoonjans et al,QDVVRFLDWLRQZLWKWKHSURPRWLRQRISHUR[LVRPDOȕ-oxidation 
(through effects on enzymes such as acyl-CoA oxidase) this increases the availability of 
IDWW\DFLGVIRUPLWRFKRQGULDOȕ-oxidation.  Within the mitochondrion both the expression 
of medium-chain acyl-&R$ GHK\GURJHQDVH LQYROYHG LQ ȕ-oxidation) and the 
mitochondrial form of hydroxymethylglutaryl-CoA synthase (involved in ketone body 
V\QWKHVLVLVVWLPXODWHGE\33$5ĮDFWLYDWLRQ*XOLFNet al, 1994; Rodriguez et al, 1994). 
 
$ ULVH LQ JOXFRFRUWLFRLG FRQFHQWUDWLRQ ZLOO VWLPXODWH WKH H[SUHVVLRQ RI 33$5Į
(Lemberger et al, 1994), and so stress situations and fasting, which lead to a rise in the 
concentrations of glucocorticoids, also lead to an increase in the e[SUHVVLRQ RI 33$5Į
mRNA and protein.  In contrast to this finding, insulin has been demonstrated to lead to a 
UHGXFWLRQLQWKHH[SUHVVLRQRI33$5ĮLQUDWOLYHU6WHLQHJHUet al, 1994). 
 
 33$5ȕį 
Analysis of samples from human subjects has demonstrated moderate expression of 
33$5ȕį LQ DOO WLVVXHV WHVWHG RIWHQ DW KLJKHU OHYHOV WKDQ WKH RWKHU WZR 33$5V ZLWK
increased expression in tissue of placental and colonic origin (Mukherjee et al, 1997; 
Auboeuf et al, 1997).  Little is currently understood about the reJXODWLRQ RI 33$5ȕį
expression, but it has been suggested that PPARȕįPD\VHUYHDVDJHQHUDOUHJXODWRURI
fat oxidation (Wang et al, 2003) or to compensate for reduced expression of the other 
PPAR isoforms in the tissues where this is low. 
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 33$5Ȗ 
33$5Ȗ Ls expressed abundantly in human adipose tissue (Mukherjee et al, 1997; 
Auboeuf et al, 1997), but is also expressed in several transformed human B lymphocyte 
and myeloid cell lines as well as in primary bone marrow stromal cells in culture (Greene 
et al, 19,WH[LVWVLQWZRSURWHLQLVRIRUPVȖDQGȖZKLFKGLIIHULQWKDWWKHȖIRUP
has 28 additional amino acids on the NH2-WHUPLQDOVLGHLQKXPDQV7KHȖLVRIRUPLVWKH
dominant form in human adipose tissue (Rosen and Spiegelman, 2001). 
 
The regulatioQ RI WKH 33$5Ȗ JHQH KDV EHHQ H[WHQVLYHO\ VWXGLHG GXH WR LWV NH\ UROH LQ
adipogenesis and as a receptor for insulin-VHQVLWL]LQJGUXJV,QGXFWLRQRI33$5ȖP51$
has been observed in vitro following the exposure of adipocytes to both insulin and 
corticosteroids (Vidal-Puig et al, 1997).  The same group demonstrated that the adipose 
WLVVXH RI REHVH KXPDQ VXEMHFWV ZDV IRXQG WR KDYH LQFUHDVHG H[SUHVVLRQ RI 33$5Ȗ
P51$DVZHOO DV DQ LQFUHDVH LQ WKH UDWLRRI33$5Ȗ WR33$5ȖZKLFKZDV UHGXFHG
following a low caloULH GLHW  5HVHDUFKHUV KDYH FRQFOXGHG WKDW 33$5Ȗ H[SUHVVLRQ LQ
adipose tissue does not correlate with BMI or fasting blood insulin concentration from a 
study conducted in 29 subjects with varying degrees of obesity (Auboeuf et al, 1994) and, 
based upon these findings, it has been suggested by Desvergne and Wahli (1999) that in 
KXPDQV33$5ȖLVLQYROYHGLQWKHFRQWURORIDGLSRF\WHIXQFWLRQUDWKHUWKDQ33$5Ȗ,Q
D VWXG\ H[DPLQLQJ 33$5Ȗ H[SUHVVLRQ LQ VNHOHWDO PXVFOH (Kruszynska et al, 1998) an 
increase in expression was detected in both obese non-diabetic and patients with type 2 
diabetes mellitus in direct relation to their BMI and fasting blood insulin concentration.  
$OWKRXJK PXWDWLRQV LQ 33$5Ȗ KDYH EHHQ DVVRFLDWHG ZLWK ORZHU %0, DQG LQFUHDVHG
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insulin sensitivity in non-obese subjects (Deeb et al, 1998), there is no evidence of an 
association between this single mutation and either obesity or diabetes mellitus.   
 
The fibrate family of hypolipidaemic drugs (e.g. clofibrate and Wy-14,163) preferentially 
bLQG WR 33$5Į ZKLOVW WKH WKLD]ROLGLQHGLRQHV WURJOLWD]RQH SLRJOLWD]RQH DQG
URVLJOLWD]RQHDOWKRXJKGHULYHGIURPFORILEULFDFLGVHOHFWLYHO\ELQG33$5Ȗ/HKPDQQet 
al ,QVXOLQHQKDQFHVWKHWUDQVFULSWLRQDODFWLYLW\RIWKH33$5Ȗ$)-1 (Werman et 
al, 19DVZHOODVLQGXFLQJWKHDFWLYLW\RIWKH33$5Į$)-1 domain (Juge-Aubry et al, 
1999) suggesting that insulin induces phosphorylation of PPAR via a mechanism that 
may involve posttranslational modification of an auxiliary factor (Desvergne and Wahli, 
1999). 
 
In skeletal muscle stimulation of PPARȕį E\ DGPLQLVWUDWLRQ RI WKH VHOHFWLYH DJRQLVW
GW501516 leads WRDQLQFUHDVHLQIDWW\DFLGȕ-oxidation and a marked increase in PDK4 
expression (Tanaka et al, 2003).  Following the administration of high-fat diet the same 
researchers also noted a significant improvement in glucose tolerance and insulin 
sensitivity through a mechanism that is currently unclear.  They suggested that PPARȕį
may direct metabolism from the utilisation of carbohydrate towards the utilisation of fatty 
DFLGVYLDȕ-oxidation. 
 
33$5ĮKDVDVWLPXODWRU\HIIHFWRQKXPDQVNHOHWDOPXVFOH3'.JHQHH[SUHVVLRQ0XRLR
et al, 2002).  Through this effect it is suggested that during states of high fatty acid 
availability, such as diabetes and fasting, the reduction in PDC activation will increase 
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the sparing of glucose derived carbons from metabolism (as the increase in fatty acid 
R[LGDWLRQ FDSDFLW\ DQG NHWRQH ERG\ V\QWKHVLV VHHQ IROORZLQJ 33$5Į DFWLYDWLRQ LQ WKH
liver will already allow for the preservation of carbohydrate derived fuel), allowing for 
their use in hepatic glucose production.  The oxidation of fatty acids and ketone bodies in 
oxidative muscle spares glucose stores during periods of reduced glucose availability 
(e.g. fasting) as well as limiting the requirement for hepatic gluconeogenesis from muscle 
protein catabolism. 
 
The proportion of energy derived from fat oxidation at a given exercise intensity is 
increased following endurance training, and this is thought to be related to changes in 
PPAR controlled gene expression rather than changes in the intramuscular fatty acid 
concentration, as basal levels are similar in both trained and untrained human subjects 
(Hurley et al, 1986).  The relative expression LQ VNHOHWDOPXVFOHRI33$5ȕį LVJUHDter 
WKDQ33$5ĮZKLFKLQWXUQLVJUHDWHUWKDQ33$5Ȗ*LOGHDQG9DQ%LOVHQ33$5
controlled gene expression may be involved in the response of skeletal muscle fat 
oxidation, and fuel selection during endurance exercise, to changes in intramuscular fatty 
acid concentrations (Kiens, 2006).  This suggestion is supported by the finding that 
PPARȕį-null mice are only able to sustain 30-40% of the running time and distance of 
control mice (Wang et al, 2004). 
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Aims 
The aim of this thesis is to determine the role of the pyruvate dehydrogenase in the 
regulation of human skeletal muscle metabolism.  It is suggested that PDC activation, 
either by DCA infusion or exercise, and PDC inhibition through high-fat feeding will 
influence the selection of fuel for subsequent bouts of contraction.   
 
In order to investigate this I intend to take muscle biopsies from human volunteers during 
exercise following pyruvate dehydrogenase activation, by DCA infusion.  At low 
intensity exercise the contribution of energy for contraction is predominantly from a fat-
derived source (van Loon et al, 2001), and my hypothesis is that PDC activation using 
DCA will alter fuel selection towards carbohydrate derived rather than fat derived 
sources, with a reduction in metabolic inertia at the onset of contraction due to the more 
efficient provision of ATP from carbohydrate metabolism.   
 
The secondary aim of this thesis would investigate the effect of PDC activation at rest 
upon the ventilatory threshold.  DCA pre-treatment had previously been demonstrated to 
reduce the blood lactate concentration in humans at rest and during contraction (Timmons 
et al, 1998a; Howlett et al, 1999a) and I therefore hypothesise that if the lactate and 
ventilatory threshold are linked through an increase in VCO2 occurring from increased 
buffering of H+ derived from lactic acid dissociation, then DCA pre-treatment will lead to 
an alteration in the onset of the ventilatory threshold.    
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As a tertiary aim I will investigate the effect of PDC activation on human volunteers after 
high-fat feeding.  Previous research has demonstrated that increasing the availability of 
fatty acids results in an upregulation of PDK and corresponding PDC inhibition (Putman 
et al, 1993; Peters et al, 2001), which reduces the contribution of carbohydrate oxidation 
to skeletal muscle energy provision at the onset of contraction.  Administration of DCA, a 
systemic PDK inhibitor, is hypothesised to reverse the inhibition of PDC induced by 
high-fat feeding.   
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Chapter 2. 
 
GENERAL METHODS 
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Human Volunteers. 
Healthy men under the age of 40 years were recruited into all of the studies in this thesis 
by poster advertisement from the University of Nottingham student body.  All the studies 
were approved by the ethics committee of the University of Nottingham Medical School 
in accordance with the declaration of Helsinki (1964), and subjects were not permitted to 
take part if they had participated in another study within the last 3 months.  Written 
information was provided upon initial subject enquiries, and further verbal information 
was given prior to obtaining written consent to enrol in the studies. All subjects were free 
to withdraw from the study at any time.  Each participant was required to attend a health 
screening visit prior to participation in any of the experimental visits.  This initial visit 
consisted of a general health questionnaire, as well as measurements of height, weight, 
resting blood pressure and haematological (full blood count) and biochemical (urea and 
electrolyte and liver function tests) indices.  These blood samples (approximately 8 
millilitres) were obtained by venepuncture of the superficial veins within the antecubital 
fossa using a closed Vacutainer system and analysed by the Departments of Haematology 
and Clinical &KHPLVWU\4XHHQ¶V0HGLFDO&HQWUH1RWWLQJKDP8. 
 
After successful completion of the initial health screening visit, subjects visited the 
laboratory on the morning of the experiment after fasting from midnight having abstained 
from alcohol and strenuous exercise for at least 24 hours.  A record of all procedures was 
kept, and medical cover was present at all times.  All visits were separated by a two week 
period to ensure similar basal plasma and muscle concentrations between experimental 
visits. 
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Dichloroacetate Infusions. 
During visits within each experiment subjects received an intravenous infusion of sodium 
dichloroacetate (50 mg.kg-1, which is equal to 0.33 mmol.kg-1) for 30 or 60 minutes.  
Sodium dichloroacetate was obtained from Fluorochem Limited (Derby) and, after 
quality control testing, was prepared by the Sterile Production Department (Queens 
Medical Centre, Nottingham) to a concentration of 25 mg.ml-1.  Following the antegrade 
insertion of an 18-gauge intravenous cannula (Venflon, Becton Dickinson, New Jersey, 
USA) into a forearm vein the required dose was infused over a sixty (Chapter 3), thirty 
(Chapter 4) or forty-five (Chapter 5) minute period.  In the latter two experiments this 
infusion was then followed by thirty or forty-five minutes of supine rest.  This dose has 
been demonstrated in previous studies within the School of Biomedical Sciences 
(Constantin-Teodosiu et al, 1999; Timmons et al, 1998b) to completely activate the 
pyruvate dehydrogenase complex in healthy human volunteers. 
 
Blood Sampling. 
On arrival in the laboratory during the experimental visits of Chapters 4 and 5 an 18-
gauge intravenous cannula was retrogradely inserted into a distal forearm or hand vein 
and the hand kept in a hand warming device (air temperature approximately 55 degrees 
C) to arterialise the venous blood (Gallen & Macdonald 1990) and an infusion of 0.9% 
saline chloride solution (Maco Pharma Ltd, London, UK) was used to ensure continued 
patency of the cannula.   
 
 64 
During the visits of Chapters 4 and 5 five millilitres of arterialised venous blood were 
obtained for immediate analysis of blood glucose and lactate concentration.  During the 
visits of Chapter 5 two millilitres of this blood were placed into lithium heparin 
containers and centrifuged for 14,000 rpm for 2 minutes.  This plasma was then removed 
and immediately frozen in liquid nitrogen, after which it was stored at -80 degrees C for 
later analysis for free fatty acid (FFA) concentration. 
 
Blood Analysis. 
Blood glucose and lactate concentrations.  
Glucose concentrations were determined in a small sample of blood, immediately after 
withdrawal from the sampling cannula, using a glucose/lactate analyser (YSI 2300 
STATplus, Yellow Springs Instruments, Ohio, USA). The analyser was calibrated using 
glucose and lactate standards of known concentration (YSI, Yellow Springs, Ohio, USA).  
 
Plasma non-esterified fatty acid.  
Plasma non-esterified fatty acid (NEFA) concentration was determined using an 
enzymatic-colorimetric assay kit (NEFA C kit, WAKO Chemicals GmbH, Neuss, 
Germany). FiYH ȝO VDPSOH RU VWDQGDUG  -  ȝPROO-1) were incubated in a 96-well 
plate for 10 min at 37 &ZLWKȝORIUHDJHQW$ZKLFKFRQWDLQHGDF\O-CoA synthetase 
(ACS), ATP, and CoASH. The acyl-CoA, formed from endogenous NEFA or oleic acid 
standard by the action of ACS (Reaction 2), was then oxidised to hydrogen peroxide by 
WKH DGGLWLRQ RI  ȝO RI UHDJHQW % 5HDFWLRQ  ZKLFK FRQWDLQHG DF\O-CoA oxidase 
(ACO), and incubated for a further for 10 min at 37 C. 
 65 
NEFA + ATP + CoASH  Acyl-CoA + AMP + PPi [2] 
Acyl-CoA + O2    2, 3-trans-enoyl-CoA + H2O2 [3] 
 
Reagent B also contained peroxidase, which allowed the oxidative condensation of 3-
methyl-N-ethyl-N-ȕ-hydroxy-ethyl)-aniline (MEHA) with 4-aminoanti pyrine to form a 
purple coloured solution, the light absorption of which was measured on a 
spectrophotometer (Spectra Max 190, Molecular Devices Ltd, Sunnyvale, California, 
USA) at 550 nm. The NEFA concentration in mmol.l-1 was calculated using the slope of 
the regression line from the standard curve. The regression coefficients were usually 
>0.9995.  
 
Plasma ammonia. 
Two millilitres of blood were mixed with EGTA and centrifuged.  The resultant plasma 
was snap frozen in liquid nitrogen and then analysed for ammonia content according to 
the methods described by Neeley and Phillipson (1988). 
 
Muscle Sampling. 
Muscle biopsies were obtained (Chapters 3 and 5), whilst subjects rested in a supine 
position, from the vastus lateralis (m. quadriceps femoris) using the percutaneous needle 
biopsy technique (Bergström, 1962). Briefly, the skin around the area on the thigh to be 
sampled was shaved (if necessary) and then cleaned using an iodine solution. Thereafter, 
following a small incision (<1 cm) in the skin and fascia using a scalpel blade under local 
anaesthetic (1% lignocaine HCl, B. Braun, Melsungen, Germany), a 5 mm gauge 
ACS 
ACO 
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Bergström biopsy needle (Bignell Surgical Instruments Ltd, West Sussex, UK) was used 
to take a small sample of muscle (50±200 mg wet weight) which was then immediately 
frozen in liquid nitrogen. When more than one biopsy was taken, a distance of at least 2.5 
cm was allowed between the prospective sites in order to minimise the effects of an 
inflammatory response on muscle metabolite concentrations (Constantin-Teodosiu et al, 
1996). The sampling time between insertion of the needle, withdrawal, and plunging into 
liquid nitrogen lasted no more than 10 s.  
 
Muscle Analysis. 
Muscle metabolite extraction. 
Approximately two-thirds of each muscle biopsy sample was subsequently freeze-dried 
over night (Edwards Freeze Dryer Modulyo), powdered, and stored at -80 C for 
metabolite extraction and analysis at a later date. The muscle powdering procedure took 
place at room temperature using a pestle and mortar for 20 min (per sample) under a lamp 
and magnifying glass with all visible blood and connective tissue being removed. The 
UHPDLQLQJ PXVFOH WLVVXH ZDV VWRUHG µZHW¶ LQ OLTXLG QLWURJHQ DQG XVHG IRU WKH
determination of mRNA (Chapter 5) and pyruvate dehydrogenase complex activity 
(Chapters 3 and 5) analysis at a later date.  
 
The extraction of the membrane bound metabolites, contained within the powder, was 
performed by the addition of ice-cold 0.5M PCA, containing 1mmol.l-1 EDTA to each 
aliquot of powdered muscle.  Samples were then kept on ice over a period of 10 minutes 
with each one, in turn, being subjected to aggressive vortexing.  Extracts were then 
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centrifuged (for 2 minutes at 14000 rpm) and the resulting supernatants removed and 
neutralised with 2.2 mol.l-1 KHCO3.  Extracts were then re-centrifuged, followed by the 
removal and storage of their supernatants at -80 C for later analysis.  The extraction 
dilution factor (F) for each sample was calculated as follows: 
 
F = VolPCA x (VolSUP + VolKHCO3) 
     VolSUP x WtMUS 
Where: 
 VolPCA   9ROXPHRI3&$DGGHGȝO 
 VolSUP   9ROXPHRI3&$VXSHUQDWDQWȝO 
 VolKHCO3 = Volume of KHCO3 DGGHGWRWKH3&$H[WUDFWȝO 
 WtMUS  = Weight of the muscle powder (mg) 
 
Muscle ATP, PCr, creatine, glucose-6-phosphate, lactate and glycogen determination. 
Muscle glucose-6-phosphate (G-6-P), ATP and PCr concentrations were determined 
spectrophotometrically in NADPH/NADH linked reactions (Harris et al.  1974) as 
outlined below: 
Glucose-6-phosphate + NADP+  P-gluconolactone + NADPH + H+ 
ATP + Glucose  ADP + Glucose-6-phosphate + H+ 
Phosphocreatine + ADP + H+   Creatine + ATP 
Briefly, the absorbances at 340 nm of microcuvettes containing all components of the 
reaction mixture (including sample/blank/standard), other than hexokinase (HK), 
glucose-6-phosphate dehydrogenase (G-6-PDH) and creatine phosphokinase (CPK) were 
G-6-PDH 
HK 
CPK 
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measured giving absorbance-1 (A1).  Absorbances were also measured following the 
addition of G-6-PDH, giving absorbance-2 (A2), following the addition of HK, giving 
absorbance-3 (A3), and following the addition of CPK, giving absorbance-4 (A4), to the 
reaction mixture.  Following addition of each enzyme, cuvettes were incubated at room 
temperature with constant agitation on a rotating plate until the reaction had reached a 
plateau.  Changes in absorbance measurements of samples were used to calculate G-6-P, 
ATP and PCr concentrations of the samples using the following calculations: 
[G-6-P] mmol.kg-1 dry muscle = (V2 (A2 ± Bl2) ± V1 (A1 ± Bl1)) x F 
   6.22 x SV 
[ATP] mmol.kg-1 dry muscle = (V3 (A3 ± Bl3) ± V2 (A2 ± Bl2)) x F 
   6.22 x SV 
[PCr] mmol.kg-1 dry muscle = (V4 (A4 ± Bl4) ± V3 (A3 ± Bl3)) x F 
   6.22 x SV 
Where: 
 V1  = Initial reaction volume (ȝO 
V2  = V1 + volume of G-6-3'+ȝO 
V3   9YROXPHRI+.DGGHGȝO 
V4   9YROXPHRI&3.DGGHGȝO 
A1 (or Bl1) = Initial absorbance of reagent + sample (or blank) in cuvette 
A2 (or Bl2) = Absorbance following addition of G-6-PDH to sample (or blank) 
A3 (or Bl3)  = Absorbance following addition of HK to sample (or blank) 
A4 (or Bl4) = Absorbance following addition of CPK to sample (or blank) 
F  = Extraction dilution factor 
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6.22  = Millimolar absorption coefficient of NADPH at 340 nm 
SV  = Sample Volume 
 
Muscle creatine concentration was determined by a similar method using NADH linked 
reactions in accordance with the method of Harris et al. (1974) outlined below: 
Pyruvate + NADH + H+  lactate + NAD+ 
ADP + phosphoenolpyruvate + H+    ATP + pyruvate 
Creatine + ATP  phosphocreatine + ADP + H+ 
The absorbances at 340 nm of microcuvettes containing all components of the reaction 
mixture (including sample/blank/standard) other than CPK were measured (A1).  
Following the addition of CPK and incubation until the reaction has reached its end-point 
(constant rate of decline in absorbance), absorbances of cuvettes were measured (A2).  
Changes in absorbance measurements of samples were also used to calculate creatine 
(Cre) concentration of the samples using the following calculation: 
[Cre] mmol.kg-1 dry muscle = (V2 (A2 ± Bl2) ± V1 (A1 ± Bl1)) x F 
   6.22 x SV 
 
Muscle lactate concentration was determined by a similar method using an NADH linked 
reaction in accordance with the method of Harris et al. (1974) outlined below: 
Lactate + NAD+  pyruvate + NADH + H+ 
The absorbances at 340 nm of microcuvettes containing all components of the reaction 
mixture (including sample/blank/standard) other than LDH were measured (A1).  
Following the addition of LDH and incubation until the reaction has reached a plateau, 
LDH 
PK 
CPK 
LDH 
 70 
absorbances of cuvettes were measured (A2).  Changes in absorbance measurements of 
samples were also used to calculate lactate concentration of the samples using the 
following calculation: 
[Lactate] mmol.kg-1 dry muscle = (V2 (A2 ± Bl2) ± V1 (A1 ± Bl1)) x F 
   6.22 x SV 
Muscle glycogen content was determined by the method of Harris et al (1974) and 
utilized 0.5 ± 4.0 mg of freeze dried muscle powder.  Muscle glycogen concentration was 
determined by an assay that first involved hydrolysis of glycogen by heating at 80 C for 
10 minutes in 100 ± ȝORIPROO-1 NaOH, followed by neutralization with 400 ± 
ȝORIEXIIHUHG+&OUDWLRRIPROO-1 citric acid/0.2 mol.l-1 Na2HPO4 buffer : 
0.1 mol.l-1 HCl).  This mixture was then incubated at room temperature for 60 minutes in 
the presence of 15 ± ȝODPLQRJOXFRVLGDVHDQGWKHVXSHUQDWDQWVWRUHGDW- 80 C for the 
subsequent determination of glucose content of sample, standards and blanks.  The 
extraction dilution factor (FGLY) of the sample was then calculated by the following 
equation: 
FGLY = VolEXT + WtMUS 
WtMUS 
Where: 
VolEXT  = Sum of all extraction reagent volumes. 
The concentration of glycosyl units in the glycogen digests were determined 
spectrophotometrically in NADH linked reactions in accordance with Harris et al (1974) 
as outlined below: 
ATP + Glucose  ADP + Glucose-6-phosphate + H+ 
HK 
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Glucose-6-phosphate + NAD+  P-gluconolactone + NADH + H+ 
The absorbance at 366 nm of microcuvettes containing all the components of the reaction 
mixture (including sample/blank), other than HK and G-6-PDH were measured (A1/Bl1).  
Following addition of HK and G-6-PD and incubation until the reaction had reached a 
plateau, absorbances of cuvettes were measured (A2/Bl2).  Changes in absorbance 
measurements of samples and blanks were used to calculate glycosyl concentrations of 
the samples using the following calculation: 
[Glucose] mmol.l-1 dry muscle = [((A2 x V2) ± (A1 x V1)) ± ((Bl2 x V2) ± (Bl1 x V1))] x FGLY 
3.34 x SV 
Where: 
 3.34 = millimolar absorption coefficient of NADH at 366 nm. 
 
After removal of visible blood and connective tissue, the freeze-dried muscle samples 
were powdered and analyzed for acetylcarnitine content using a modified version of the 
radioenzymatic method of Cederblad et al. (1990).  
 
Muscle acetyl-CoA, free-CoASH, acetylcarnitine and free carnitine determination. 
Acetyl-CoA, free-CoASH, acetylcarnitine and free carnitine were determined from the 
perchloric acid muscle extracts used for ATP, PCr and creatine according to the 
radioisotopic assays of Cederblad et al (1990).  Briefly, the determination of acetyl-CoA 
was composed of two isotopic reactions.  Firstly fresh [14C]-oxaloacetate was produced 
from [14C]-aspartate by aspartate aminotransferase in accordance with Cooper et al 
  7KH VHFRQG UHDFWLRQ FRQGHQVHV WKH VDPSOH¶V DFHW\O-CoA with the [14C]-
oxaloacetate forming [14C]-citrate in the presence of citrate synthase as outlined below: 
G-6-PDH 
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L-[14C]-aspartate + 2-oxoglutarate  [14C]-oxaloacetate + L-glutamate 
[14C]-oxaloacetate + acetyl-CoA  [14C]-citrate + CoASH 
Any remaining [14C]-oxaloacetate was transaminated back to [14C]-aspartate enabling the 
[14C]-citrate to be recovered, by the addition of 1 ml of Dowex (H+) resin (18 g/30 ml 
reagent grade water) removing the negatively charged [14C]-aspartate from the 
supernatant.  Sample radioactivity was determined within a 0.5 ml aliquot of the 
supernatant, to which 5 ml of scintillation fluid was added, with each sample being 
counted over 5 minutHV  5DFNEHWDU ȕ-liquid scintillation counter, LKB Wallac).  
An acetyl-CoA standard curve (0 ± 125 pmol; r > 0.9999) was run in duplicate within 
each batch of analysis. 
To determine the concentration of acetylcarnitine, the perchloric acid muscle extractions 
used for ATP, PCr and creatine were further diluted (10:100) with reagent grade water.  
%ULHIO\DFHW\OFDUQLWLQH¶VDFHW\OJURXSZDVWUDQVIHUUHGWR&R$6+LQDUHDFWLRQFDWDO\VHG
by carnitine acetyltransferase, as outlined below: 
Acetylcarnitine + CoASH  acetyl-CoA + carnitine 
The resulting acetyl-CoA was then determined, in the common step, as described 
previously.  An acetylcarnitine standard curve (0 ± 125 pmol; r > 0.9999) was run in 
duplicate within each batch of analysis.  Each sample was run once. 
Free carnitine was assessed by using the carnitine acetyltransferase reaction and [14C]-
acetyl-CoA.  The labelled acetyl group was transacetylated onto the endogenous carnitine 
forming [14C]-acetylcarnitine, as outlined below: 
[14C]-acetyl-CoA + carnitine   [14C]-acetylcarnitine + CoASH 
 73 
An L-carnitine standard curve (0 ± 3600 pmol; r > 0.9999) was run in duplicate with each 
batch of analysis.  Each sample was run once.  The reaction was stopped by passing the 
reaction brew through a 5 cm column of Dowex (Cl-) resin (1 x 8-100, Mesh 200 ± 400) 
which retains the excess [14C]-acetyl-CoA and allows the Dowex to be regenerated 
following a salting out process. 
 
Muscle metabolite correction for total creatine concentration. 
All samples, whenever possible, were analysed for the same metabolite on the same day 
using the same batch of enzyme and made up reagents.  Samples were analysed in a blind 
manner, where the order of the samples was unknown until the later checking of records.  
This was done to prevent any user bias.  All metabolites that cannot move freely between 
the intracellular and extracellular spaces (ATP, phosphocreatine, glucose-6-phosphate, 
creatine and acetylcarnitine) were corrected for the average total creatine concentration 
(PCr + creatine) within the study population.  By this means it is possible to compensate 
for any admixture of connective tissue and other non-muscular elements within each 
individual muscle biopsy sample (Hultman and Sjöholm, 1983). 
 
Pyruvate dehydrogenase complex activation status. 
The PDC activation status was assessed using the method described by Constantin-
Teodosiu et al (1991).  This analysis optimised ~4 mg chipped wet samples, stored under 
liquid nitrogen, prepared previously.  Briefly, the assay involves the measurement of 
PDC that exists in its active moiety (PDCa) at the time of extraction.  This assay is 
possible for PDC as activation in vivo is as a result of covalent modification, which 
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survives the extraction procedure (Hansford, 1994).  Following homogenisation and 
extraction the amount of PDC in its active state was conformationally locked by the 
addition of DCA and NaF to the buffer, to inhibit the intrinsic kinase (PDK) and 
phosphatase (PDP) respectively.  The rate this preparation converted 1 mM of added 
pyruvate into acetyl-CoA, over the course of a 3 minute period, was then investigated.  
The resultant acetyl-CoA was determined as described previously.  All samples were run 
in duplicate and blanks performed by substituting water for pyruvate in the reaction brew, 
each day.  PDCa was expressed as mmol acetyl-CoA.min-1.(mg protein)-1, but as protein 
content has been seen to hardly vary between samples (Constantin-Teodosiu, personal 
communication) the rate was expressed as a specific activity with units of mmol acetyl-
CoA.min-1.(kg wet muscle)-1 at 37 C.  Each sample was run once and had a CV of 5.0%. 
 
Real time PCR.  
Total RNA was isolated from snap frozen muscle using RNA plus (Qbiogene) according 
WRWKHPDQXIDFWXUHU¶VSURWRFRO)LUVWVWUDQGF'1$ZDVWKHQV\QWKHVLVHGIURPȝJ51$
sample using random primers (Promega) and PowerScript Reverse Transcriptase (BD 
Biosciences).  
Taqman PCR was carried out using an ABI prism 7000 sequence detector (Applied 
%LRV\VWHPV 86$ ZLWK  ȝO RI F'1$  ȝ0 RI HDFK SULPHU  ȝ0 SUREH DQG
8QLYHUVDO7DTPDQ[3&50DVWHUPL[(XURJHQWHFLQDȝOILQDOYROXPH(DFKVDPSOH
was run in triplicate, in duplex reactions. Cyclophilin A labelled with the fluorescent dye 
VIC was used as internal control, while all genes of interest were labelled with the 
fluorescent reporter FAM. The thermal cycling conditions used were: 2 min at 50 C, 10 
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min at 95 C, followed by 40 cycles at 95 C for 15 sec and 60 C for 1 min. Ct values of the 
target gene were normalized to Ct values of the internal control cyclophilin A, and the 
final results were calculated according to the 2- Ct method. The group of vehicle treated 
rats was used as calibrators with a value of 1. 
 
Statistical Analysis. 
$OO GDWD ZLWKLQ WKLV WKHVLV DUH UHSRUWHG DV PHDQV  6(0 FDOFXODWHG XVLQJ 0LFURVRIW¶V
Excel 2003 spreadsheet package.  Comparisons between treatments, for both absolute 
concentrations and changes from rest, were carried out using two-way (time and 
treatment) analysis of variance (ANOVA) with repeated measures, unless otherwise 
stated in the text, by use of the specialised statistical package SPSS (Version 12.0 for 
Microsoft Windows).  When a significant F value was found, accepted at or below the 
5% level, an LSD post-hoc analysis was performed to locate differences.  Pearson 
correlation coefficients were used for describing linear relationships and linear regression 
was used in the determination of the concentration of carnitine, CoASH and their 
acetylated forms. 
 
Calculation of ATP production from substrate level phosphorylation. 
The amount of ATP produced from non-oxygen dependent routes; better termed substrate 
level phosphorylation (SLP) was calculated from changes in the concentration of muscle 
PCr, lactate and ATP using the following equation: 
SLP (mmol.(kg dry muscle)-1)  ǻ>3&U@[ǻ>PXVFOHODFWDWH@[ǻ>$73@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Where: 
ǻ = Difference in concentration of stated metabolite between two biopsy 
sampling points. 
It was taken that the lactate formed was derived solely from glycogen and hence the net 
yield of ATP derived from glycolysis here would be 3 per glucosyl unit.  Therefore, when 
calculated from lactate the yield becomes 1.5 since each glucosyl unit yields 2 molecules 
of lactate.  Due to the stochiometric rise in [IMP] concentration when muscle ATP 
concentratiRQIDOOVWKHQHW\LHOGRIµATP-HTXLYDOHQWV¶LQYROYLQJWKHP\RNLQDVHUHDFWLRQLV
the equivalent of 2 ATPs for every 1 mmol.(kg dry muscle)-1 change in concentration 
(Spriet et al 1987). 
 
Coefficients of Variation for analytical measurements. 
The co-efficients of variation (CV) for the measurement of substrate and metabolite 
concentrations within blood and muscle samples are expressed as percentages and 
presented in Table 2.1.  The CV % was determined by repeated measurements of the 
same sample ten times and was calculated as follows: 
CV % = Standard deviation of repeated measurement  x 100 
Mean of repeated measurement  
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Tissue Measurement n CV % 
    
Blood Glucose 10 1.2 
 Lactate 10 1.0 
    
Muscle G-6-P 10 0.5 
 ATP 10 0.6 
 PCr 10 0.8 
 Creatine 10 1.0 
 Lactate 10 0.9 
 Glycogen 10 1.3 
 Acetyl-CoA 10 3.9 
 Free-CoASH 10 3.9 
 Acetylcarnitine 10 3.9 
 Free Carnitine 10 3.9 
 PDCa 10 5.0 
 
Table 2.1 Coefficient of variances for analytical measurements.  Number of trials (n) 
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Chapter 3. 
 
THE CONTRIBUTION OF PYRUVATE DEHYDROGENASE 
COMPLEX ACTIVATION TO OXIDATIVE ENERGY RELEASE 
DURING LOW INTENSITY EXERCISE 
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Introduction. 
The lag in oxidative ATP delivery that occurs at the onset of steady-state exercise, 
characterised by a rapid hydrolysis of muscle phosphocreatine (PCr) and accumulation of 
lactate, has been attributed by some to an inertia in mitochondrial ATP production 
(Yoshida et al, 1995; Grassi et al, 1998a, 1998b), rather than the classically accepted 
theory of a delay in muscle oxygen delivery (Margaria et al, 1965). Moreover, it appears 
WKDW WKLV µPHWDEROLF LQHUWLD¶ UHVLGHV DW WKH OHYHO RI WKH VNHOHWDO PXVFOH S\UXYDWH
dehydrogenase complex (PDC).  
 
The PDC is covalently regulated by two competing enzymes, a Ca2+-dependent 
phosphatase, which dephosphorylates pyruvate dehydrogenase (PDH) and transforms the 
enzyme to the active form, and a kinase, which catalyses the ATP-dependent 
phosphorylation of PDH and inactivates the enzyme complex (Wieland, 1983). The 
outcome of this antagonism determines the amount of PDC existing in a non-
phosphorylated, active form (PDCa). The flux through the PDC reaction (its catalytic 
activity), is dependent on the amount of PDCa and the availability of pyruvate, free 
coenzyme A (CoASH) and NAD+. It appears that, whilst pyruvate production is important 
to the magnitude of flux through the PDC reaction in vivo, it is of little importance to the 
magnitude of PDCa; increased muscle Ca2+ availability, as a result of muscle contraction, 
and insulin are most likely the principal activators of PDC transformation in vivo 
(Mandarino et al, 1987; Constantin-Teodosiu et al, 1991a, 2004; Putman et al, 1995). As 
a result of the PDC reaction, pyruvate and CoASH are oxidized to acetyl-CoA, while 
NAD+ is reduced to NADH. The acetyl group formed is either further oxidized in the 
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tricarboxylic acid (TCA) cycle or, when the availability of acetyl-CoA becomes greater 
than its rate of entry into TCA cycle, is sequestered by carnitine to form acetylcarnitine 
(Childress et al, 1966; Constantin-Teodosiu et al, 1991a).  
 
It has been demonstrated in ischemic contracting canine and human skeletal muscle 
(Timmons et al, 1997, 1998a; Roberts et al, 2002a), and in humans during bicycling 
exercise under normoxic conditions (Howlett et al, 1999a), that pharmacological 
activation of the PDC, using dichloroacetate (DCA; a systemic PDC kinase inhibitor), 
resulted in a stockpiling of acetyl groups (i.e. acetyl-CoA and acetylcarnitine) at rest and 
reduced PCr hydrolysis and lactate accumulation compared to control at the onset (i.e. 
within the first min) of subsequent muscular contraction. This research suggested that 
there is a period during the rest-to-work transition when acetyl group availability does not 
meet the energy demands of contraction due to a lag in PDC activation, resulting in non-
oxidative ATP production. Indeed, Roberts et al (2002a) demonstrated in canine gracilis 
muscle (where 5 muscle biopsies were taken over the first minute of contraction) that a 
ODJLQDFHW\OJURXSSURYLVLRQDQµDFHW\O-JURXSGHILFLW¶RFFXUUHGGXULQJWKHLQLWLDOVRI
contraction, which resulted from, and was mirrored by, a lag in PDC activation. Thus, 
these investigations collectively established the activation of the PDC as a rate-limiting 
step in the rate of rise in mitochondrial ATP production in skeletal muscle at the onset of 
contraction, which in turn will dictate the magnitude of non-oxidative ATP production, 
and thereby the rate of fatigue development during contraction. 
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The above studies investigated the metabolic inertia at the level of PDC at the onset of 
moderate to high intensity muscle contraction.  It has been demonstrated that at the onset 
of very high intensity bicycling exercise (Howlett et al, 1999b; Savasi et al, 2002) or one-
legged knee-extensor exercise (Bangsbo et al, 2002) in humans during normoxic 
conditions, DCA administration does not alter non-oxidative ATP provision or muscle O2 
uptake during the rest-to-work transition compared to control. This would suggest that 
there is an upper workload intensity above which acetyl group delivery is no longer 
limiting towards TCA cycle demand, most likely due to the rapid, Ca2+-induced 
activation of PDC at this exercise intensity (Putman et al, 1995; Howlett et al, 1998). 
Timmons et al (2004) hypothesised, and demonstrated, that when the initial rate of PCr 
degradation at the onset of very high intensity exercise exceeded approximately 1 
mmol (kg dm)-1 s-1, the priming of oxidative metabolism with DCA was not readily 
measurable, most probably because the exercise intensity employed did not rely on a 
large enough contribution from mitochondrial ATP production and, therefore, was 
unlikely to be influence by acetyl group availability.  In contrast to these findings, it is 
suggested that during low intensity exercise the magnitude of metabolic inertia will be 
less, as the rate of ATP demand will be lower and will be better matched by the rate of 
PDC activation and flux at the onset of exercise. In line with this hypothesis, it was 
demonstrated that increasing muscle acetyl group availability independently of PDCa, by 
intravenously infusing sodium acetate, had no effect on muscle PCr degradation or lactate 
accumulation, compared to control, in healthy human volunteers bicycling at 65% 
VO2max (Evans et al, 2001). However, although both the increase in PDCa and the 
stockpiling of acetyl groups in resting muscle contribute to reducing inertia in 
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mitochondrial ATP production at the onset of subsequent contraction, the former is 
quantitatively more important (Roberts et al, 2001) and, to date, has not been investigated 
during low intensity exercise under normoxic conditions.  
 
The aim of the present study was, therefore, to investigate whether metabolic inertia at 
the level of PDC would be overcome at the onset of exercise <65% VO2max in human 
skeletal muscle, by pre-treatment with DCA. Furthermore, it is not known whether the 
reported effect of DCA on PDCa persists over more than one bout of exercise, and, 
therefore, an additional aim of the present study was to investigate the effect of DCA on 
PDC activation during a second bout of exercise following a period of resting recovery. 
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Methods. 
Subjects 
Nine healthy, non-smoking, non-vegetarian young men (age 27 ± 2 yr, body mass 77.4 ± 
3.6 kg, body mass index 24.0 ± 0.8 kg m-2) participated in the present study.  Upon entry 
to the study each participant performed a continuous, incremental exercise test to 
exhaustion on an electrically braked cycle ergometer (Lode Excalibur, Lode, Groningen, 
The Netherlands) to determine their maximal rate of oxygen consumption (VO2max), 
measured using an on-line analysis system (SensorMedics, Anaheim, CA, USA), which 
was confirmed 3 days later. The mean VO2max for the group was 43.0 ± 1.9 ml min-1 kg-
1
.  
 
Experimental protocol 
Each subject reported to the laboratory at 0900h on two occasions, separated by a 2-week 
washout period, and voided their bladder. All subjects had abstained from alcohol and 
strenuous exercise for the previous 48 h. On arrival, subjects were asked to rest in a 
supine position on a bed while a cannula was placed in an antecubital vein in the non-
dominant forearm. At t=0, dichloroacetate (DCA; Fluorochem Ltd., Derby, UK), or the 
equivalent volume of 0.9% saline (CON; Baxter Healthcare, Northampton, UK), was 
intravenously infused at a rate of 50 mg kg-1 h-1 for 1 h. Thereafter, the cannula was 
removed and subjects commenced two-legged cycling exercise on an electrically braked 
cycle ergometer (Lode Excalibur, Lode, Groningen, The Netherlands) for 6 min at a 
predetermined workload equivalent to 60% VO2max (195 ± 12 W), whilst maintaining a 
pedalling frequency of 70 rpm. Following a 15 min resting period, subjects performed 
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another 6 min bout of bicycling exercise at 60% VO2max. Perceived exertion, assessed 
using the Borg Ratings of Perceived Exertion scale (Borg, 1970), and heart rate were 
recorded every minute during the exercise bouts.   
 
Sample collection and analysis 
Muscle biopsy samples were obtained from the vastus lateralis muscle immediately 
before and after each bout of exercise using the percutaneous needle biopsy technique 
(Bergstrom, 1975), and were snap frozen in liquid nitrogen less than 5s after removal 
from the limb. These biopsies were taken as the major changes in skeletal muscle PDC 
activation occur rapidly, but changes in ATP and PCr are constant throughout exercise 
from 6 minutes onwards (Karlsson and Saltin, 1970). One portion of the sample was 
subsequently freeze-dried and stored at -80 degrees C, and the remainder was stored 
³ZHW´LQOLTXLGQLWURJHQ 
 
Statistical analysis and calculations 
A two-way ANOVA (time and treatment effects; GraphPad Prism 4.02, GraphPad 
Software Inc, CA) was performed to locate differences in muscle PDCa and muscle 
carnitine, acetylcarnitine, glycogen, lactate, PCr, ATP and glucose-6-phosphate content. 
:KHQDVLJQLILFDQWPDLQHIIHFWZDVGHWHFWHGGDWDZHUHIXUWKHUDQDO\VHGZLWK6WXGHQW¶V
paired t tests using the Bonferroni correction. Statistical significance was declared at 
P<0.05, and all the values presented in text, Tables, and Figures are means ± standard 
error of the mean (SEM). ATP production derived from substrate level phosphorylation 
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ZDV FDOFXODWHG IURP ǻ3&U  [ ǻODFWDWH   [ ǻ$73 ZKHUH ǻ LV WKH GLIIHUHQFH
between pre and post exercise concentrations. 
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Results. 
Heart rate and perceived exertion 
There was no difference between either group with respect to heart rate and perceived 
exertion at the end of the two bouts of exercise. Borg scale values were the same (14 ± 1) 
at the end of both exercise bouts in both visits. Heart rate was 153 ± 5 vs. 153 ± 7 and 
161 ± 5 vs. 159 ± 6 beats min-1 for control and dichloroacetate pre-treated groups at the 
end of the first and second exercise bouts, respectively.  
 
PDC activation status 
Skeletal muscle PDCa before and after the two bouts of exercise in the CON and DCA 
visits is presented below (figure 3.1). As previously demonstrated, muscle PDCa 
increased following the first bout of exercise within the control group from a basal value 
of 0.5 ± 0.1 to 1.5 ± 0.1 mmol acetyl-CoA min-1 (kg wet muscle)-1 (p<0.01). Thereafter, 
muscle PDCa returned to basal following the 15 min resting recovery period (0.9 ± 0.1 
mmol acetyl-CoA min-1 (kg wm)-1), which then increased significantly following the 
second bout of exercise (1.7 ± 0.1 mmol acetyl-CoA min-1 (kg wm)-1; p<0.01).  
 
Pre-treatment with intravenous dichloroacetate resulted in a 4-fold greater resting muscle 
PDCa compared to the control group (1.9 ± 0.3 mmol acetyl-CoA min-1 (kg wm)-1; 
p<0.01). Following the first bout of exercise PDCa remained elevated in DCA compared 
to the control group following the first bout of exercise (2.1 ± 0.3 mmol acetyl-CoA min-
1 (kg wm)-1).  This increase in PDCa was also detected before and after the second bout  
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Figure 3.1 Muscle PDC activation.  Muscle PDCa before (pre) and after (post) two 6 
min bouts of cycling exercise at 60% VO2max, separated by 15 min rest, following 1 h of 
intravenous 0.9 % saline (CON; white blocks) or dichloroacetate (DCA; black blocks) 
infusion.  *p<0.01 vs. corresponding pre-exercise value.  p<0.05 DCA vs. CON. 
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of exercise when compared to the control group (2.0 ± 0.1 and 1.9 ± 0.1 mmol acetyl-
CoA min-1 (kg wm)-1, respectively; p<0.05).  
 
Muscle metabolites 
Figure 3.2 shows skeletal muscle acetylcarnitine content before and after the two bouts of 
exercise in both visits. Muscle acetylcarnitine content increased following the first bout 
of exercise in the control group from 1.5 ± 0.4 to 9.5 ± 1.2 mmol (kg dry muscle)-1 
(p<0.01). Following the 15 min resting recovery period muscle acetylcarnitine content 
remained elevated above basal (4.6 ± 0.8 mmol (kg dm)-1; p<0.05), and then increased 
further compared to basal following the second bout of exercise (10.8 ± 1.2 mmol (kg 
dm)-1; p<0.01).  
 
Pre-treatment with dichloroacetate resulted in a 5.5-fold greater resting muscle 
acetylcarnitine content when compared to the control group (8.3 ± 0.8 mmol (kg dm)-1; 
p<0.01). When compared to the basal value within the control group, muscle 
acetylcarnitine content remained elevated in DCA following the first bout of exercise 
(11.0 ± 1.1 mmol (kg dm)-1; p<0.01) and before and after the second bout of exercise (6.7 
± 1.0 and 8.9 ± 1.1 mmol (kg dm)-1, respectively; p<0.01). 
 
Other skeletal muscle metabolite contents before and after the two bouts of exercise in 
the both visits are presented in Table 3.1. Muscle ATP and glucose-6-phosphate content 
remained constant throughout all time points in both visits in both the control and 
dichloroacetate pre-treated groups.  Muscle phosphocreatine content decreased from  
 89 
 
Figure 3.2 Muscle acetylcarnitine content.  Muscle acetylcarnitine content before (pre) 
and after (post) two 6 min bouts of cycling exercise at 60% VO2max, separated by 15 min 
rest, following 1 h of intravenous 0.9% saline (CON; white blocks) or dichloroacetate 
(DCA; black blocks) infusion.  *p<0.05 vs. corresponding pre-exercise 1 value, p<0.05 
vs. corresponding pre-exercise value.  **p<0.05 DCA vs. CON. 
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Table 3.1 Muscle metabolites. 
 Exercise bout 1 Exercise bout 2 
 CON DCA CON DCA 
 Pre Post Pre Post Pre Post Pre Post 
ATP 25.4 ± 1.6 24.5 ± 1.6 26.2 ± 1.0 23.5 ± 1.3 22.5 ± 2.2 23.8 ± 1.8 23.8 ± 2.1 22.2 ± 1.9 
PCr 71.0 ± 2.1 63.0 ± 4.0 74.4 ± 3.1 57.0 ± 4.0 71.5 ± 4.1 65.6 ± 3.0 73.3 ± 7.0 63.7 ± 4.6 
Lactate 5.3 ± 0.9 35.7 ± 6.7 3.7 ± 0.8 33.8 ± 7.2 11.7 ± 2.0* 31.9 ± 5.7 12.0 ± 3.0* 30.0 ± 6.9 
Glycogen 321 ± 33 266 ± 35 320 ± 40 222 ± 30 273 ± 33 185 ± 33 216 ± 22* 197 ± 22 
Glucose-6-P 4.0 ± 0.3 5.1 ± 0.4 4.0 ± 0.6 4.7 ± 0.5 3.1 ± 0.4 4.7 ± 0.3 4.3 ± 0.5 6.2 ± 0.7 
Carnitine 13.1 ±1.6 6.3 ± 0.5 7.5 ± 0.8** 4.2 ± 0.6 ** 10.7 ± 0.8 5.6 ± 0.6 7.7 ± 1.1** 5.6 ± 1.1 
Values are means ± SEM expressed as mmol.(kg dm)-1.  *p<0.05 vs. corresponding pre-exercise 1 value, p<0.05 vs. corresponding 
pre-exercise value.  **p<0.05 DCA vs. CON. 
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basal to a similar degree following the first exercise bout in control (p<0.05) and 
DCA pre-treated (p<0.01) groups. Following this PCr content returned to basal 
following the 15 min resting recovery period and decreased from basal following the 
second bout of exercise in both visits (p<0.05).  There was no difference between 
groups at any point with regard to muscle phosphocreatine content. 
 
Muscle lactate increased above basal to the same extent in both control and DCA pre-
treated groups following the first exercise bout (p<0.01) and remained elevated above 
basal following the 15 min resting recovery period and the second bout of exercise 
(p<0.01).  There was no difference in muscle lactate content between groups at any 
time point in this study. 
 
Following the first exercise bout, muscle glycogen content decreased below basal in 
control and DCA pre-treated groups (p<0.05).  It remained at that content following 
the 15 min resting recovery period (p<0.05), and decreased further following the 
second bout of exercise in both groups (p<0.01).  There was no difference in muscle 
glycogen content between groups detected at any time point in this study. 
 
Muscle carnitine content decreased following the first bout of exercise in the control 
group (p<0.01), and remained below basal following the 15 min recovery period 
(p<0.05).  This then decreased further compared to basal following the second bout of 
exercise (p<0.01). Intravenous DCA infusion resulted in around a 2-fold lower resting 
muscle carnitine content compared to controls (p<0.01). Furthermore, muscle 
carnitine content remained lower in the DCA pre-treated group compared to the basal 
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control value following the first bout of exercise and before and after the second bout 
of exercise (p<0.01). 
 
The calculated contribution from ATP production derived from substrate level 
phosphorylation was the same for both groups following the two bouts of exercise 
(55.5 ± 11.9 vs. 68.0 ± 12.3 and 33.6 ± 8.6 vs. 39.9 ± 16.6 mmol (kg dm)-1, 
respectively, p>0.05). However, ATP production from substrate level phosphorylation 
was less during the second bout of exercise in both groups (time effect p<0.05).   
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Discussion. 
The primary aim of the present study was to investigate whether a metabolic inertia, at 
the level of the PDC, could be overcome by DCA pre-treatment at the onset of low 
intensity bicycling exercise in human skeletal muscle under normoxic conditions. In 
this respect, the most significant finding of the present study was that, despite a 4-fold 
increase in resting muscle PDCa (Fig. 3.1) and a 5.5-fold increase in resting muscle 
acetylcarnitine content (Fig. 3.2), there was no significant effect of DCA infusion on 
muscle PCr degradation or lactate accumulation during 6 min of exercise at 60% 
VO2max compared to control (Table 3.1). Indeed, there was no effect of DCA pre-
treatment on calculated substrate level phosphorylation (SLP) during exercise 
compared to control (Fig. 3.3), which is in contrast to that routinely observed during 
moderate to high intensity exercise.  This finding could suggest that the magnitude of 
metabolic inertia at the level of PDC is minimal at the onset of low intensity exercise, 
as the rate of ATP demand will be lower and could therefore be better matched by the 
rate of PDC activation and flux. It should be noted, however, that the effect of PDC 
activation, by DCA pre-treatment, on non-oxidative ATP production at the onset of 
low intensity exercise (<60% VO2max) has been previously investigated (Timmons et 
al, 1998b; Parolin et al, 2000). In contrast to the present study, both of these studies 
demonstrated a metabolic inertia (i.e. increased muscle PCr degradation and lactate 
accumulation after 1, 8, and 15 min of contraction) at the level of the PDC at the onset 
of low intensity exercise. However, in the study by Timmons et al (1998b) single leg 
knee extensions were performed, and in the study of Parolin et al (2000) bicycling 
exercise was performed under hypoxic conditions whilst breathing 11% O2. Both of 
these exercise conditions resulted in a considerably greater PCr degradation during 
control compared to the present study, and hence, the potential for a reduction in non-
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oxidative ATP production with DCA pre-treatment. Thus, this is the first study to 
investigate the effect of DCA on PDCa and non-oxidative ATP production during low 
intensity dynamic exercise under normoxic conditions.   
 
The magnitude of PDCa is central to the control of acetyl-CoA delivery to the TCA 
cycle and carbohydrate oxidation in contracting skeletal muscle, and, as such, PDCa 
increases at the onset of exercise, from its relatively inactive or low state at rest, in 
parallel with exercise intensity up to an intensity of 90% VO2max, when the rate of 
carbohydrate oxidation becomes maximal (Constantin-Teodosiu et al, 1991a; Howlett 
et al, 1998). The premise that the intensity of exercise influences the magnitude of the 
delay in PDC activation at the onset of contraction, particularly under normoxic 
conditions, is also supported by studies involving exercise with an intensity greater 
than 90% VO2max (Howlett et al, 1999b; Savasi et al, 2002; Bangsbo et al, 2002). 
Similarly, if exercise intensity is low enough not to rely on a significant contribution 
from non-oxidative ATP production at the onset of exercise, then one would expect 
not to see an effect of DCA pre-treatment. Indeed, PCr stores were only reduced by 
around 10% in CON at the exercise intensity employed in the present study. Thus, as 
previously suggested by Roberts et al (2002a), it would appear that a metabolic inertia 
will exist at the onset of contraction over a predictable range of exercise intensities 
under normoxic conditions (between 65 and 90% VO2max), above and below which 
increasing PDCa and resting acetyl group availability via DCA pre-treatment will be 
ineffective at reducing non-oxidative ATP production and improving contractile 
function. 
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Figure 3.3 ATP production from substrate level phosphorylation. 
Calculated total ATP production derived from substrate level phosphorylation after 
two 6 min bouts of cycling exercise at 60% VO2max, separated by 15 min rest, 
following 1 h of intravenous saline (CON; white blocks) or dichloroacetate (DCA; 
EODFNEORFNVLQIXVLRQp<0.05, exercise bout 2 significantly lower than exercise bout 
1. 
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In accordance with previous human studies (Constantin-Teodosiu et al, 1999; Gibala 
et al, 1999), the infusion of 50 mg kg-1 DCA prior to the first exercise bout resulted in 
a significant increase in PDC activation. Consequently, there was a substantial 
accumulation of muscle acetylcarnitine, and most probably acetyl-CoA, in DCA at 
rest, thus providing readily available substrate for oxidative ATP production at the 
onset of exercise (muscle acetyl-CoA content is directly related to acetylcarnitine 
content, albeit at a different order of magnitude; Carlin et al, 1990; Constantin-
Teodosiu et al, 1991a). Previous studies that have calculated the contribution of 
oxidative flux to ATP production at the onset of exercise, by measuring the relative 
accumulation of acetyl groups in the form of acetylcarnitine, have demonstrated that 
the difference in acetylcarnitine accumulation during exercise between DCA and 
control corresponds to the difference in calculated SLP (assuming 1 mol of 
acetylcarnitine is oxidised to 12 mol of ATP equivalents; Timmons et al, 1997; 
Roberts et al, 2002b). However, despite approximately a 5 mmol (kg dm)-1 greater 
accumulation of muscle acetylcarnitine during both bouts of exercise in CON of the 
present study (equating to around 60 mmol (kg dm)-1 of ATP), there were no 
differences in SLP between the groups during either exercise bout, suggesting that 
oxidative ATP production was the same (assuming work output was the same). A 
possible explanation for the discrepancy between acetylcarnitine accumulation and 
SLP during exercise in the present study, compared to the previously mentioned 
studies, could be that the contribution from fat to oxidative ATP production was 
greater in CON compared to DCA, particularly as the contribution from fat oxidation 
during CON will be greater at 60% VO2max than at higher exercise intensities (van 
Loon et al, 2001). Indeed, the acetylation of the carnitine pool at rest in DCA was 
such that free carnitine availability could have been limiting to fat oxidation during 
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the exercise bout (van Loon et al, 2001; Stephens et al, 2006), thus increasing the 
reliance on carbohydrate oxidation. Studies in vitro have demonstrated that when the 
concentration of TCA cycle intermediates is low, as observed at the onset of 
contraction (Gibala et al, 1998), carnitine reduces the rate of acetyl-CoA oxidation by 
the TCA cycle (Childress et al, 1966). This effect would have been ameliorated in the 
DCA group as carnitine availability was reduced at rest as a result of DCA pre-
treatment (Table 3.1). Whatever the mechanism(s), it appears that DCA switched fuel 
use towards carbohydrate oxidation during exercise in the present study, particularly 
as muscle glycogenolysis was 2-fold greater in DCA compared to CON during the 
first exercise bout (Table 3.1). However, because the workload during exercise was of 
insufficient intensity to require a significant provision of acetyl groups for entry into 
the TCA cycle from carbohydrate oxidation in CON, then an increase in carbohydrate 
oxidation and PDCa with DCA pre-treatment would not be expected to alter the 
requirement for SLP to meet the demand for ATP production. It is also worth noting 
when carbohydrate oxidation is increased that up to 12% less oxygen utilisation is 
required for the same ATP production than when using fat as a fuel, which may 
explain why some investigations have failed to demonstrate a measurable change in 
pulmonary VO2 kinetics at the onset of during high intensity exercise with DCA pre-
treatment (Jones et al, 2004).  
 
A second aim of the present study was to investigate the effect of DCA on PDC 
activation during a second bout of exercise. PDCa increased in CON following the 
first bout of exercise at 60% VO2max to a similar degree as reported previously 
(Constantin-Teodosiu et al, 1991a), and remained elevated in DCA (Fig. 3.1). A novel 
finding from the present study was that, whereas PDCa returned towards basal 
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following the 15 min resting period in CON, PDCa remained elevated in DCA (Fig. 
3.1). Furthermore, PDCa remained elevated in DCA following the second bout of 
exercise (Fig. 3.1). Available data from previous studies that have administered up to 
100 mg kg-1 DCA, and measured skeletal muscle PDCa in healthy human volunteers, 
demonstrates that DCA maintains maximal PDC activation for up to 15 min of 
contraction (Gibala et al, 1999; Parolin et al, 2000). In the present study total exercise 
time was 12 min, and there was a 15 min rest interval between the two exercise bouts. 
Thus, the present study demonstrates, for the first time, that a 1 h intravenous infusion 
of 50 mg kg-1 DCA can sustain maximal PDC activity for more than one bout of 
exercise over a period of at least 30 min. This finding could be important if DCA is to 
be used as a metabolic tool to investigate the regulation of PDCa or therapeutically in 
the treatment of repeated episodes of muscle fatigue and pain and exercise intolerance 
in certain cardiovascular diseases (e.g. peripheral vascular disease).  
 
Another interesting finding during the second bout of exercise in the present study 
was that SLP was 40% less in both CON and DCA (Fig. 3.3). Previous research 
within the School of Biomedical Sciences (Roberts et al, 2005) has shown that 
administration of sodium acetate, which markedly increased the availability of acetyl-
CoA and acetylcarnitine in resting canine skeletal muscle independent of PDC 
activation, decreased the contribution from SLP by 40% during the first minute of 
subsequent muscle contraction (when the PDC was largely inactive) compared to 
control. Similarly, Campbell-2¶6XOOLYDQ et al (2002) also demonstrated that 
performing a bout of high intensity exercise (75% VO2max) 3 min following the 
performance of short duration low intensity exercise (55% VO2max), which increased 
muscle acetylcarnitine content 2-fold greater than at rest but did not affect PDCa, was 
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associated with a 40% reduction in SLP and an acceleration of VO2 on-kinetics in 
healthy male volunteers. However, in the present study the lower SLP during the 
second bout of exercise in CON is unlikely be due to the higher acetylcarnitine 
content (Fig. 3.2) accumulated during the first bout of exercise as this data indicated 
that acetyl group availability was not limiting to oxidative ATP production during the 
first bout of exercise. Furthermore, there was no difference in muscle acetylcarnitine 
content (Fig. 3.2) and PDCa (Fig. 3.1) before the onset of exercise between the first 
and second exercise bouts in DCA. Taken together, this would suggest that during low 
intensity exercise factors other than a metabolic inertia at the level of PDC may limit 
oxidative ATP production. Such factors are not discernable from the present study, 
EXW SHUKDSV KLJKOLJKW WKH ZHOO UHSRUWHG EHQHILWV RI ³ZDUPLQJ XS´ EHIRUH H[HUFLVH
which have classically been attributed to an exercise induced elevation of muscle 
temperature and/or the augmentation of local muscle blood flow. 
 
In conclusion, although PDCa and acetylcarnitine content was increased in muscle at 
rest, DCA had no effect on muscle PCr hydrolysis or lactate accumulation during 
exercise in the present study, supporting the suggestion that the magnitude of 
metabolic inertia at the level of PDC is minimal in the first six minutes of low 
intensity exercise.  Furthermore, the effects of DCA on PDCa can persist during 
recovery between two bouts of exercise, which could have important implications if 
DCA is to be used therapeutically. 
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Chapter 4. 
 
CHANGES IN THE VENTILATORY THRESHOLD IN 
EXERCISE DURING CONDITIONS OF NORMAL AND 
REDUCED BLOOD LACTATE CONCENTRATION 
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Introduction. 
ThHYHQWLODWRU\WKUHVKROGFDQEHGHILQHGDV³WKHSRLQWDWZKLFKWKHUHLVDQRQ-linear 
LQFUHDVHLQYHQWLODWRU\UDWHLQUHODWLRQWRR[\JHQFRQVXPSWLRQ´:LOOLDPVDQG
has been suggested and used as a method for indicating exercise performance in 
healthy and disease states within both an adult and paediatric population (Seiler et al, 
2007; Roels et al, 2005; Thomas et al, 2007; Ohuchi et al, 1996).  It is believed to 
occur at least in part due to a fall in the blood pH, arising from, amongst other things, 
an increase in the muscle production of lactic acid that at physiological pH values 
completely dissociates to form hydrogen and lactate ions.   
 
7KHODFWDWHWKUHVKROGVRPHWLPHVUHIHUUHGWRDVWKHµDQDHURELF¶WKUHVKROGZDVGHILQHG
DV ³Whe first sudden and sustained increased in blood lactate above the near-resting 
concentrations´ :DVVHUPDQ et al, 1973) and was thought to occur at the point at 
which demand for ATP to maintain contraction exhausted the ability of oxygen 
dependent mechanisms to supply it.  Increased non-oxygen dependent ATP 
regeneration, most notably by glycolysis, leads to increased generation of lactate 
which is then released to the circulation.  From this reasoning it was therefore 
assumed that the lactate threshold indicated the ability oI DQ LQGLYLGXDO¶V VNHOHWDO
muscle to generate energy aerobically, which was greater in trained individuals, and 
could therefore be used as a predictor of aerobic exercise performance (Bentley et al, 
2007). 
 
The release of lactic acid into the circulation, as well as directly determining the 
lactate threshold, leads to an increased production of CO2, through the buffering of the 
hydrogen ions by bicarbonate.  There is therefore an increase in VCO2, which leads to 
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an increase in the rate of ventilation in order to exhale the excess CO2.  The rate of 
ventilation during exercise may also be influenced by an increase in the mitochondrial 
NADH/NAD+ ratio (i.e., increase in the redox potential).  The increase in 
mitochondrial NADH above that of NAD+ is transmitted to the cytosol, where it 
activates lactate dehydrogenase (LDH) and leads to lactate formation.   
 
There is growing evidence that the accumulation of lactate at the onset of skeletal 
muscle contraction occurs due to inertia in mitochondrial ATP production (Yoshida et 
al, 1995; Grassi et al, 1998a; Grassi et al, 1998b), rather than a consequence of the 
oxygen deficit (Margaria et al, 1965).  At an exercise intensity below 90% VO2max 
this inertia has been suggested to reside at the level of the pyruvate dehydrogenase 
complex in humans during bicycle exercise in normoxic conditions (Howlett et al, 
1999), which may indicate that the rise in lactate concentration may instead reflect a 
³VSLOO-RYHU´RUE\-product of pyruvate production as the rate of glycolysis increases 
with exercise intensity.   
 
Katz and Sahlin (1990) discussed the link between oxygen dependency and lactate 
formation in their review.  They demonstrated that muscle oxygen uptake (VO2) is 
unchanged when measured at the mouth during exercise when the muscle¶s response 
to lactate is altered, either by previous aerobic training or the presence of hypoxia.  
They surmised that a reduction in oxygen present within the muscle resulted in an 
increased concentration of NADH, ADP and inorganic phosphate (Pi).  This induced 
an increased rate of glycolysis, increasing the cytosolic concentration of NADH, 
which in turn activated LDH.  Whilst they believed that other factors would influence 
the formation of lactate within the muscle during sub-maximal exercise, the reduction 
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of oxygen availability was believed to be of major importance to the rate of formation 
of lactate. 
 
Roberts et al (2005), following the work of Timmons et al (1998; 1997; 1996) 
however demonstrated in an isolated canine muscle model with fixed oxygen 
availability that the generation of lactate in the rest to work transition was instead 
dependent upon activation of the pyruvate dehydrogenase complex (PDC).  They 
suggested that the previously described oxygen deficit is in a large part dependent 
upon acetyl-CoA availability and that by ensuring near maximal activation of the 
PDC, with corresponding acetylation of the muscle carnitine and CoASH pools, they 
were able to reduce the formation of metabolic by-products (such as lactate ions, 
hydrogen ions and inorganic phosphate). 
 
During exercise in which there is a high ATP turnover rate and low phosphocreatine 
availability there is an increase in the activation of AMP deaminase (Katz et al, 1986) 
leading to production of ammonia ions (NH4+) from adenine nucleotide catabolism.  
The reamination of IMP during contraction is thought to be slow (Katz et al, 1986), 
and recovery of adenine nucleotides is believed to occur during the recovery period.  
Research in human volunteers undergoing intense dynamic single legged exercise 
demonstrated that the total net ammonia formed corresponded with the total 
accumulation of muscle inosine 5-monophosphate, suggesting that the ammonia 
produced during this exercise was derived from AMP deamination (Graham et al, 
1990).  Therefore any delay in oxygen dependent mitochondrial ATP production, and 
associated increase in flux through AMP deaminase, would be associated with a rise 
in plasma ammonia levels. 
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Dichloroacetate (DCA) is a potent systemic inhibitor of pyruvate dehydrogenase 
kinase, an intrinsic enzyme of the pyruvate dehydrogenase complex which 
phosphorylates and inactivates the complex.  Pre-treatment with DCA has been shown 
to increase PDC activation at rest to levels seen during intense exercise (Timmons et 
al, 1998) with a subsequent reduction in phosphocreatine breakdown (Parolin et al, 
2000). Previous research has demonstrated that pre-treatment with DCA in human 
volunteers undergoing both high (Rossiter et al, 2003) and moderate (Jones et al, 
2004) intensity exercise had no effect upon VO2 kinetics, despite a significant lactate 
lowering effect.   
 
After pre-treatment with 35 mg.kg-1 dichloroacetate, Carraro et al (1989) 
demonstrated a lower blood lactate concentration during exercise in healthy human 
volunteers at workloads less than 80% of maximal oxygen uptake and during the 
recovery period from exercise.  They noted that DCA pre-treatment neither altered the 
time taken to reach exhaustion (defined in this study as the inability to maintain pedal 
speed at a rate of 60 rpm on the cycle ergometer) nor the blood lactate concentration 
at exhaustion.  However whilst the concept of the anaerobic threshold was addressed 
within this paper, there was no measurement of the effects of DCA upon this 
threshold. 
 
The aim of the present study was to assess whether activation of the pyruvate 
dehydrogenase complex using DCA, with a corresponding reduction in blood lactate 
concentration, would influence the onset of the ventilatory threshold during 
continuous incremental exercise commencing at 50% VO2max.  It also aims to 
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demonstrate that pre-treatment with DCA, and the corresponding reduction in 
phosphocreatine breakdown during contraction, would lead to a reduction in the delay 
of mitochondrial (oxygen dependent) ATP production at the ventilatory threshold and 
therefore a reduced ammonia efflux from the muscle. 
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Methods. 
Subjects 
Eight healthy recreationally active male volunteers were recruited to take part in this 
study.  The mean (range) age, body mass index and peak oxygen uptake (VO2max) 
were 29.2 (24-40) years, 25.5 (21.6±33.5) kg.m-2 and 48.9 (31.4-62.3) ml.kg-1.min-1 
respectively.  Following a thorough explanation of the experimental protocol, written 
informed consent for entry into the study was obtained from all subjects prior to 
enrolment.  At least one week prior to the first study visit each subject underwent 
estimation of their maximal oxygen uptake (VO2max) using an on-line analysis 
system (SensorMedics, Anaheim, CA, USA) during continuous incremental exercise 
to exhaustion on a cycle ergometer.  This study was approved by the University of 
Nottingham Ethics Committee. 
 
Experimental procedure 
Monosodium dichloroacetate (DCA) was purchased from Fluorochem Limited 
(Derby, UK) and prepared on the day of the study for sterile infusion at a 
concentration of 25 mg.ml-1 by the sterile production unit at the Queens Medical 
Centre, Nottingham.  Subjects rested in a supine position and a retrograde 21 gauge 
cannula was inserted into a forearm vein to allow blood samples to be taken.  This 
hand was placed within a warmer (maintained at an air temperature of approximately 
55 degrees C) to arterialise the venous drainage of the hand (Gallen and Macdonald, 
1990).  An antegrade 21 gauge cannula was also inserted into a separate forearm vein 
for infusion.  Each subject received, in a randomised crossover fashion, 50 mg.kg-1 
body mass of dichloroacetate or an equivalent volume of saline (CON, 0.9% NaCl 
solution; Baxter Healthcare, Northampton, UK) over a 30 minute period, followed by 
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30 minutes of supine rest.  The subject then commenced incremental exercise on a 
cycle ergometer (Lode Excalibur, Lode, Groningen, The Netherlands) commencing at 
50% of VO2 max, increasing by 25 watt increments every four minutes with 
measurements of heart rate (averaged over the preceding minute) recorded for the last 
minute of every increment.  Throughout exercise exhaust gases were collected for 
breath by breath online gas analysis (SensorMedics, Anaheim, CA, USA).  Exercise 
was ceased at the next incremental increase in intensity after the subject was judged to 
have reached the ventilatory threshold (detected by an inflection point in VE/VO2 
without concomitant rise in VE/VCO2 (Caiozzo et al, 1982)). 
 
Sample collection and analysis 
Three millilitres of arterialised-venous blood were taken at the end of every increment 
for immediate analysis of blood glucose and lactate (Yellow Springs Instrument 
lactate analyser, Columbus, OH).  The remaining blood was mixed with EGTA and 
centrifuged.  The resultant plasma was snap frozen in liquid nitrogen and then 
analysed for ammonia content according to the methods described by Neeley and 
Phillipson (1988).  The subjects remained seated for 20 minutes following the 
cessation of exercise whilst further measurement of expired gases and blood 
metabolites were taken.  After a washout period (minimum duration of seven days) 
the subjects returned to the laboratory and repeated the same protocol with the 
alternate infusion.   
 
Statistical analysis and calculations 
End points measured included the comparison between treatment groups of 
respiratory variables and blood metabolites over time.  The data were analysed using 
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two-way analysis of variance for repeated measures (ANOVA) with two within 
subject factors (time and trial). When the ANOVA test results in a significant F ratio 
(PWKHORFDWLRQRIWKHGLIIHUHQFHZDVLGHQWLILHGXVLQJ6FKHIIH¶VWHVW 
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Results. 
Respiratory/Ventilatory data. 
The results for the control group demonstrate a steady increase in ventilation (VE) 
throughout exercise (Figure 4.1), with maximum first derivative of the 
time/ventilation curve detected between 17 and 18 minutes of exercise.  
Measurements of oxygen consumption (VO2) showed a steady increase for each 
minute throughout exercise once a steady state had been achieved.  Measurements of 
CO2 production (VCO2) showed a steady increase throughout exercise, with a similar 
inflection point in the time/VCO2 curve detected as with ventilation. 
 
Following DCA pre-treatment a similar steady increase in ventilation was seen during 
incremental exercise.  There was also an inflection point in the time/ventilation curve 
detected between 17 and 18 minutes of exercise.  After achieving a steady state, the 
DCA pre-treated group also showed a steady increase in VO2 throughout the period of 
exercise.  VCO2 increased steadily throughout exercise, with a similar inflection point 
in the time/VCO2 curve detected as with ventilation. 
 
Comparison of the ventilatory data between the two groups therefore revealed no 
significant difference between the two populations at any time during the study.  Nor 
was there any difference in the area under the curve for either population with respect 
to VE/VCO2 (638.31±34.75 vs. 640.19±41.36). 
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Blood metabolites. 
Lactate (Figure 4.2) 
Throughout the infusion period, there was no change in blood lactate concentration in 
the control population.  A steady increase was noted throughout exercise, with a 
marked increase during the last increment, within which the subjects reached their 
ventilatory threshold.  During the recovery period the blood lactate concentration 
returned towards normal, but at the end of the recovery period the blood lactate 
concentration was still significantly different from the resting value.  Infusion of DCA 
led to a significant fall in the resting lactate concentration as demonstrated previously 
(Roberts et al, 2005).  The changes noted during exercise were similar to those seen in 
the control group, with no difference detected between the two groups.  Whilst there 
was no difference between populations comparing absolute blood lactate 
concentration during exercise, the area under the curve (Figure 4.3), representing the 
amount of lactate produced during this period was significantly lower during exercise 
in the DCA group (50.46 ±5.2 vs. 44.28 ±5.0, p<0.01). 
 
Glucose (Table 4.1) 
Throughout the infusion period there was no change in blood glucose concentration in 
the control population.  A slight decrease was noted during exercise, with a 
corresponding increase during the rest period.  Infusion of DCA led to a fall in the 
resting blood glucose concentration (4.60 vs. 4.36, p=0.051).  Within the DCA pre-
treated population no fall in blood glucose concentration was noted during exercise, 
but at the completion of exertion there was a similar rise in glucose concentration to 
the control population. 
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Figure 4.1 Ventilation.  Ventilation during incremental cycling exercise following intravenous 0.9% saline (CON, open boxes) or 
dichloroacetate pre-treatment (DCA, closed boxes). 
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Figure 4.2 Blood lactate concentration.  Blood lactate concentration during incremental exercise and recovery following intravenous 0.9% 
saline (CON, open boxes) or dichloroacetate pre-treatment (DCA, closed boxes).  
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Ammonia (Table 4.1) 
There was no change in plasma ammonia concentration throughout the infusion 
period in the control population.  Exercise led to a steady increase in concentration 
until 16 minutes, where there was a larger increase for the final increment of exercise.  
At the completion of exercise there was a steady decline in the ammonia 
concentration to resting levels.  Infusion of DCA led to a reduction in the resting 
concentration of ammonia (83.17 vs. 63.00, p=0.04 at -30 minutes) but this was not 
present at the onset of exercise (74.67 vs. 59.00, p>0.05).  A steady increase in 
ammonia concentration was found during exercise in the DCA pre-treated population, 
with the final increment being associated with a larger rise in ammonia concentration 
than the previous increments.  As in the control population at the completion of 
exercise the ammonia concentration returned to its resting value.  During the exercise 
and recovery period there was no significant difference in plasma ammonia 
concentration.  The area under the curve, which represents the net balance of apparent 
total plasma ammonia production, release from the muscle and uptake and clearance 
by the liver, was not significantly different between groups at any time during 
exercise or recovery (Exercise 1822.4 ± 157.9 vs. 1544.8 ± 272.1, p>0.05; Recovery 
1856.8 ± 201.2 vs. 1454.4 ± 356.7, p>0.05). 
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Figure 4.3 Net lactate production.  Net lactate production during infusion (60 mins), incremental exercise (20 mins) and recovery (20 mins) 
following intravenous 0.9% saline (CON, white blocks) or dichloroacetate pre-treatment (DCA, black blocks). * p<0.01 DCA vs. CON. 
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Table 4.1  Blood metabolites.  Metabolites measured during incremental cycling exercise following intravenous 0.9% saline (CON) or 
dichloroacetate pre-treatment (DCA).  * p=0.04 (DCA vs. CON) 
 
Time (minutes) -60 -30 0 4 8 12 16 20 24 28 32 36 40 
Glucose 
(mmol.l-1) 
CON 4.73 4.67 4.76 4.44 4.53 4.39 4.47 4.57 5.10 5.19 5.09 5.06 4.93 
DCA 4.60 4.47 4.36 4.36 4.31 4.33 4.39 4.36 5.06 4.93 4.81 4.74 4.73 
Ammonia 
ȝPROO-1) 
CON 74.17 83.17* 74.67 80.33 82.33 94.00 99.33 129.17 116.17 94.67 81.83 72.83 66.17 
DCA 63.40 63.00* 59.00 63.50 67.83 73.50 82.17 104.83 90.17 72.83 62.50 52.00 45.83 
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Discussion. 
The primary aim of this study was to investigate if reducing the blood lactate 
concentration would influence the onset of the ventilatory threshold in healthy human 
volunteers during continuous incremental bicycling exercise from 50%VO2max to 
exhaustion.  With respect to this the most significant finding was that, despite a 
significant reduction in blood lactate concentration (Figure 4.2) following DCA pre-
treatment, there was no reduction in either the time taken to reach the ventilatory 
threshold (Figure 4.1) or the lactate concentration measured at and after the ventilatory 
threshold.  This finding supports the study by Carraro et al (1989) that the infusion of 
DCA did not alter the time to exhaustion, nor did it alter the lactate concentration at that 
time, despite a reduction of resting blood lactate concentration and a trend towards lower 
blood lactate concentrations during the exercise and recovery periods of the experimental 
visit.  It also supports the findings of both Rossiter et al (2003) and Jones et al (2004) that 
pre-treatment with DCA has no effect on VO2 kinetics, although this is the first study to 
demonstrate that effect during continuous incremental cycling exercise. 
 
The link between lactate and the ventilatory threshold has been cast into doubt by the 
finding that the ventilatory threshold can be detected prior to the lactate threshold (Davis 
and Gass, 1981), as well as research performed in subjects who do not produce lactate, 
who also have a non-linear increase in ventilation during exercise (Paterson et al, 1990).  
The data support the suggestion that there is another factor responsible for the non-linear 
increase in ventilation seen during exercise, and further research has suggested potassium 
as the factor that may be responsible.  Within the same population that does not produce 
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lactate (McArdles syndrome) plasma potassium levels seem to match the ventilatory 
changes better than lactate within both the exercise and recovery phases of this study.  
However McLoughlin et al (1994) found results to the contrary, and the role of potassium 
in influencing ventilatory changes is not yet clear. 
 
The lactate lowering effect of DCA pre-treatment is thought to be due to increased flux 
through the pyruvate dehydrogenase complex, which also leads to a reduction in 
phosphocreatine hydrolysis during submaximal exercise.  An increase in the activation 
state of PDC has been suggested to result in direction of more of cellular pyruvate 
production towards Acetyl-CoA production and from there onwards to acetylcarnitine, so 
as to keep the CoA available for other mitochondrial processes.  The sparing of the 
indicators of anaerobic metabolism after DCA infusion has been suggested to occur due 
to the ready availability of acetyl groups for entry into the TCA cycle.  This reduces the 
lag present during the change in mitochondrial metabolism during the rest to work 
transition, and therefore better couples oxygen dependent ATP production to the demands 
of contraction.  With a reduction in the requirement for ATP generation by anaerobic 
mechanisms, the deleterious by-products of this process are reduced and muscle function 
therefore improved.  The findings do not support a reduction in ATP generation due to 
anaerobic methods, as the total ammonia efflux seen after DCA pre-treatment was not 
significantly different to that measured in the control population.   
 
One suggestion is that this is likely due to the minimal effect of DCA infusion at the 
initial low intensity workload as noted in the previous chapter (Chapter 3).  This has 
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demonstrated no effect of DCA pre-treatment in healthy human volunteers at an exercise 
workload of below 65% VO2max, and it may be that as the activation of PDC at this 
workload within the control group is not rate limiting to the provision of ATP for skeletal 
muscle contraction, the benefits seen at higher exercise intensities are met in the control 
population by the normal increases in PDC activation and the contribution of fatty acid 
oxidation during increasing intensity of exercise. 
 
Although there was no significant difference in the blood lactate concentrations during 
exercise between groups, pre-treatment with DCA did lead to a reduction in the net 
lactate production during exercise (Figure 4.3).  This is likely to reflect a reduction in the 
formation of lactate within the contracting skeletal muscle, due to better matching of the 
oxidative ATP production and skeletal muscle demand in this group as previously 
demonstrated in both canine and human studies (Roberts et al, 2005; Timmons et al, 
1998a) during the rest to work transition. 
 
Previous research (Graham et al, 1990) has shown the measured total ammonia formation 
WREHHTXLYDOHQWWRPXVFOHLQRVLQH¶-monophosphate (IMP) accumulation, which results 
from the further catabolism of adenine nucleotides during contraction.  The same authors 
demonstrated that reamination of IMP occurs predominantly during recovery.  If ATP 
provision and utilisation for contraction is well matched then the further breakdown of 
ADP does not occur and therefore little ammonia is generated during contraction.  
However if ATP generation and utilisation are poorly matched (for example at the onset 
of exercise in the presence of metabolic inertia) then further breakdown of adenine 
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nucleotides will result in an increase in the formation of IMP and therefore an increase in 
ammonia formation.  The above results demonstrate no difference between groups with 
regard to plasma ammonia concentration at any time during the study, and if the 
assumption of Graham et al (1990) is correct then this may further suggest that the inertia 
present at the onset of low-intensity (50% VO2max) exercise is minimal. 
 
This is the first study to investigate the effect of lowering blood lactate concentration on 
the ventilatory threshold during incremental exercise.  In conclusion, the primary finding 
of this study was that a reduction in resting blood lactate concentration, using the PDK 
inhibitor dichloroacetate, did not influence the onset of the ventilatory threshold.  This 
study also demonstrated that during continuous incremental exercise commencing at 50% 
VO2max, pre-treatment with DCA did not reduce plasma ammonia concentration. 
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Chapter 5. 
 
THE POSSIBLE MOLECULAR MECHANISM RESPONSIBLE FOR 
DIETARY FAT MEDIATED INHIBITION OF PYRUVATE 
DEHYDROGENASE COMPLEX ACTIVATION IN HUMAN 
SKELETAL MUSCLE, WHICH IS NOT REVERSED BY ACUTE 
CONTRACTION 
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Introduction 
A reduction in dietary carbohydrate intake, or increase in dietary fat intake, for several 
days has been demonstrated to reduce the rate of flux through the PDC during muscle 
contraction (Putman et al, 1993) which has been attributed to a blunting of PDC 
activation or a direct inhibition of PDC flux (Putman et al, 1993).  This impairment of 
carbohydrate metabolism has been implicated in causing the metabolic syndrome, which 
consists of central obesity, glucose intolerance, hypertriglyceridaemia, hypertension and 
low HDL-cholesterolaemia (Gorter et al, 2004). 
 
The pyruvate dehydrogenase complex is the rate limiting step in the entry of glucose 
derived pyruvate into the TCA cycle, and as such plays an important role in the control of 
use of carbohydrate as the source of oxidative energy for skeletal muscle contraction.  As 
previously discussed, the PDC is regulated by a negative feedback mechanism in the 
short term, that is to say that the products of its reaction, i.e. NADH and Acetyl-CoA 
inhibit the partial reactions catalysed by the components of the enzymatic complex E1 
and E3.   Over the longer term, PDC activity is controlled by the competing actions of 
pyruvate dehydrogenase kinase (PDK) and pyruvate dehydrogenase phosphatase 
(PDP)(Wieland et al, 1983) determining the amount of non-phosphorylated (active) 
pyruvate dehydrogenase complex (PDCa). 
 
During muscle contraction in humans following a normal diet, increases in intracellular 
calcium and pyruvate appear to be the principal activators of PDC by activation of PDP 
and inhibition of PDK reactions (Constantin-Teodosiu et al, 2004).  Dichloroacetate 
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mimics the structure of pyruvate and is able to fully activate PDC in resting skeletal 
muscle by PDK inhibition.  This has been demonstrated to increase muscle carbohydrate 
oxidation during subsequent muscle contraction and has been used extensively in 
experiments examining PDC flux in skeletal muscle with normal or reduced blood flow 
(Timmons et al, 1998).  As yet, there has been no study assessing if increasing PDC 
activation through the infusion of DCA will reduce the inhibitory effects of high-fat diet 
mediated insulin resistance on carbohydrate oxidation during exercise.  
 
This study therefore aims to determine if DCA administration will reduce the stimulatory 
HIIHFWVRIKLJKIDWIHHGLQJRQPXVFOH33$5ĮDQG3.'H[SUHVVLRQLQKXPDQVWKHUHIRUH
stimulating skeletal muscle carbohydrate oxidation during exercise in healthy human 
volunteers by increasing the flux through PDC reaction. 
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Methods. 
Subjects 
Six healthy, non-smoking, non-vegetarian young men participated in the present study.  
Upon entry to the study each participant performed a continuous, incremental exercise 
test to exhaustion on an electrically braked cycle ergometer (Lode Excalibur, Lode, 
Groningen, The Netherlands) to determine their maximal rate of oxygen consumption 
(VO2max), measured using an on-line analysis system (SensorMedics, Anaheim, CA, 
USA), which was confirmed three days later.  Each subject then completed a 
familiarisation visit consisting of 60 min of cycling at the required intensity (75% 
VO2max) to ensure the accuracy of this calculation. 
 
Experimental procedure. 
Each subject then underwent three further laboratory visits (see Fig. 5.1), which were 
randomised. One YLVLWZDVSUHFHGHGE\LQGLYLGXDOVFRQVXPLQJDSUHVFULEHG³QRUPDO´GLHW
for three days (55% carbohydrate, 30% fat, 15% protein; Control visit (CON)). The 
remaining two visits involved subjects ingesting a low carbohydrate/high fat diet (10 % 
carbohydrate, 75% fat 15% protein) for three days.  Both diets were isocaloric.  Three 
days prior to each visit subjects were issued with their diet for these days.  The subjects 
were assumed to be compliant with their diet, however this was not checked.  On arrival 
at the laboratory, a cannula was inserted retrogradely into the dorsum of the hand, using 
local anaesthetic (1% lignocaine), for the sampling of venous blood. An initial 
arterialised blood sample was taken for the measurement of free fatty acids and glucose. 
The subject then received a randomised infusion of either 0.9% saline (control visit and 
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low carbohydrate/high-fat visit (FD)) or dichloroacetate (50 mg.kg-1 body weight; second 
low carbohydrate/high fat visit (FD-DCA), Fluorochem Ltd., Derby, UK) over a period 
of 45 minutes. This was then followed by 45 minutes of supine rest. Throughout this 
infusion and subsequent rest period, arterialised blood samples were collected at the time 
points indicated in Fig. 5.1. During the 45 minutes of rest following the infusion 
protocols,  three muscle biopsy sites were prepared prior to commencing exercise, using 
local anaesthetic (1% lignocaine), according to established protocol.  An initial biopsy 
was taken immediately prior to exercise using a Bergström needle (Bergström, 1975). 
The subject then commenced cycling at 75% VO2max, with continuous expired gas 
collection occurring for the initial 10 minutes of exercise for measurement of VO2 and 
VCO2. After 10 minutes, the subject briefly stopped cycling as a second muscle biopsy 
was obtained from the vastus lateralis, whilst the subject remained seated (and supported) 
on the cycle ergometer. This biopsy was required as the major changes in skeletal muscle 
PDC activation occur rapidly, but changes in ATP and PCr are constant throughout 
exercise from 3 minutes onwards (Karlsson and Saltin, 1970). The subject then continued 
cycling until 60 minutes had passed, when a final muscle biopsy was taken. Throughout 
exercise, blood samples were taken for assessment of glucose, lactate and free fatty acid 
concentrations, as well as VO2 and VCO2 estimates every ten minutes (over two 
minutes). After a seven-day washout period, the subject returned for their second visit 
and after a further seven-day washout their final visit. Thus, subjects attended three 
experimental visits in total. Each involved 3 muscle biopsy samples and 11 blood 
samples and was preceded by 3 days of normal dietary intake (Control visit; CON) or low 
carbohydrate/high fat intake (fat visit (FD) and fat + DCA visit (FD-DCA)). 
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Figure 5.1 Visit protocol.
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Sample analysis 
Three millilitres of arterialised-venous blood was taken at the end of every increment for 
immediate analysis of blood glucose and lactate (Yellow Springs Instrument lactate 
analyser, Columbus, OH).  Two millilitres of this blood were collected into lithium 
heparin containers, and after centrifugation, the plasma was removed and immediately 
frozen in liquid nitrogen. These samples were then stored at ±80 C and analyzed at a later 
date for free fatty acid (FFA) concentration, using an enzymatic-colorimetric assay kit 
(NEFA C kit; Wako Chemicals, Neuss, Germany). 
Snap frozen vastus lateralis muscle was subsequently divided into two parts whilst under 
liquid nitrogen. One part was freeze-dried, dissected free from visible connective tissue 
and blood, and powdered. Five to 10 mg of this muscle powder was then extracted with 
0.5 M perchloric acid containing 1 mM EDTA, and, after centrifugation, the supernatant 
was neutralised with 2.2 M KHCO3. Free carnitine and acetylcarnitine were measured in 
the neutralised extract by enzymatic assays that made use of a radioisotopic substrate, as 
previously described (Cederblad et al, 1990). Muscle ATP, PCr, creatine and lactate 
concentrations were determined fluorometrically using a modification of the method of 
Harris et al (1974).  Total RNA was isolated from snap frozen soleus muscle using RNA 
SOXV 4ELRJHQH DFFRUGLQJ WR WKHPDQXIDFWXUHU¶VSURWRFRO)LUVW VWUDQGF'1$ZDV WKHQ
synthesised IURPȝJ 51$VDPSOHXVLQJ UDQGRPSULPHUV 3URPHJD DQG3RZHU6FULSW
Reverse Transcriptase (BD Biosciences).  Taqman PCR was carried out using an ABI 
prism 7000 sequence detector $SSOLHG%LRV\VWHPV86$ZLWKȝORIF'1$ȝ0RI 
HDFKSULPHUȝ0SUREe, and Universal Taqman 2x PCR Mastermix (Eurogentec) in a 25 
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ȝO ILQDOYROXPH(DFKVDPSOHZDV UXQ LQ WULSOLFDWHV LQGXSOH[UHDFWLRQV&\FORSKLOLQ$
labelled with the fluorescent dye VIC was used as internal control, while all genes of 
interest were labelled with the fluorescent reporter FAM. The thermal cycling conditions 
used were: 2 min at 50oC, 10 min at 95oC, followed by 40 cycles at 95oC for 15 sec and 
60oC for 1 min. Ct values of the target gene were normalized to Ct values of the internal 
control cyclophilin A, and the final results were calculated according to the 2-ǻǻCt 
method. 
 
Statistical analysis and calculations 
All data are expressed as mean ± SEM. To investigate the treatment effect repeated 
measurements of analysis of variance (ANOVA) was applied. When a significant F-ratio 
was obtained, a LSD post-hoc test was applied to locate specific differences. Significance 
was set at the P<0.05 level of confidence. 
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Results. 
Respiratory parameters 
All subjects were able to exercise at the required intensity for 60 minutes throughout the 
study. Whole body VO2 was lower, although not to a significant degree, in CON group 
when compared to the high fat diets at the same exercise intensity (Fig. 5.2).  There was 
an initial increase in respiratory exchange ratio (RER) at the onset of exercise in all 
groups which had reached a steady state by 10 minutes of exercise, and despite the 
control group displaying a trend towards higher values there was no significant difference 
throughout all visits (Fig. 5.3). 
 
Blood metabolites 
Blood lactate concentrations prior to exercise were similar in all three treatment groups 
(Fig. 5.4). Following infusion of DCA there was a significant reduction in blood lactate 
concentration.  Upon exercise, blood lactate concentrations increased in all groups. 
However, the blood lactate concentrations during exercise in the FD-DCA diet group 
were lower than in the CON and FD groups (Fig 5.4). 
 
Plasma metabolites  
Plasma FFA concentrations prior to exercise were elevated following three days of high 
fat diet (Figure 5.5).  Infusion of DCA led to a non-significant reduction of plasma FFA 
concentration towards a similar concentration as the CON diet group, but this was not 
preserved after 45 minutes of supine rest.  During the initial 20 minutes of exercise there 
was a decrease in plasma FFA concentrations in all groups.  From this point until the 
completion of exercise there was an increase in plasma FFA concentrations in all groups.  
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However the magnitude of FFA concentration rise in the FD and FD-DCA diet groups 
was greater than in the CON group, so that by the completion of exercise there was a 
significant difference in concentration between CON and the other groups. 
 
Muscle metabolites 
Resting muscle lactate concentration was significantly lower in the FD-DCA diet group 
compared to CON and FD groups (7.4 ±1.0 vs. 8.8 ± 0.9 and 9.8 ± 1.5 mmol.kg-1 dm; 
p<0.05; Fig 5.6).  The concentration of muscle lactate after 10 minutes of contraction was 
significantly higher in the CON diet group compared to the FD and FD-DCA groups 
(47.8 ± 8.2 vs. 35.5 ± 4.0 and 38.8 ± 5.8 mmol.kg-1 dm, respectively; p<0.05).  At the 
completion of exercise there was no significant difference in the muscle lactate 
concentration. 
 
Resting muscle glycogen concentrations were significantly higher in the CON diet group 
compared with FD and FD-DCA groups (550 ± 31 vs. 428 ± 46 and 368 ± 24 mmol.kg-1 
dm, respectively; p<0.05). The decline in muscle glycogen during the whole 60 minutes, 
split for the first 10 minutes and the last 50 minutes of exercise at 75% VO2max are 
presented in Fig. 5.7. The rate of muscle glycogenolysis in the FD-DCA group was 
significantly lower compared with the CON group. This difference was entirely 
accounted for by the significantly lower muscle glycogen that occurred outside of the 
first 10 minutes of exercise in this group. 
 
Muscle PDC activation (PDCa) and the muscle acetylcarnitine concentrations are 
presented in Figs. 5.8 and 5.9 respectively. Ingestion of a high fat diet for three days 
reduced the PDCa in the FD group compared with CON group, but this did not achieve 
 130 
statistical significance. However, due to the effect of DCA infusion prior to exercise, 
PDCa increased more than 4-fold in the FD-DCA group compared with the CON group. 
 
Upon contraction, muscle PDCa significantly increased above the resting values in all 
three groups. However, the magnitude of PDC activation during the first 10 minutes of 
exercise was significantly blunted in the FD compared with the other two groups. While 
further gain in PDCa was observed in the CON group after 60 minutes of exercise, the 
PDCa remained unchanged in the FD group. The values of PDCa in the FD-DCA group 
remained elevated throughout the entire experiment.  
 
Mean resting muscle acetylcarnitine concentration in the CON group was significantly 
lower than in the FD and FD-DCA groups due to the effects of high fat diet and DCA 
infusion prior to exercise in these two groups (2.0 ± 0.5, 3.6 ± 0.5 and 10.8 ± 0.5 
mmol.kg-1 dm, respectively; p<0.05; Fig. 5.9). However, the rate of muscle 
acetylcarnitine accumulation in the FD-DCA group was significantly lower than in the 
CON and FD groups following 60 minutes of exercise. These differences were accounted 
for by the changes that had occurred during the first 10 min of exercise.  
 
Gene Expression 
The 3-day high fat diet resulted in a 3-fold raise in PDK4 mRNA at rest (Fig. 5.10), 
which was blunted after DCA treatment.  During the first 10 minutes of exercise there 
was an increase in PDK4 expression in the control and FD-DCA groups followed by a 
reduction in gene expression after 60 minutes of cycling.  Following high-fat diet, but 
without DCA treatment there was a reduction in PDK4 expression noted at both 10 and 
60 minutes.  The increase in PDK4 expression measured at rest in the fat-diet fed group  
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Figure 5.2 Percentage of maximum VO2.  Measured oxygen uptake expressed as a percentage of maximum during 60 minutes of 
cycling at 75% VO2max following 3 days of high fat or normal diet, and 45 minutes of either intravenous saline or dichloroacetate 
infusion followed by 45 minutes supine rest. 
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Figure 5.3  Respiratory Exchange Ratio.  Calculated RER during 60 minutes of cycling at 75% VO2max following 3 days of high 
fat or normal diet, and 45 minutes of either intravenous saline or dichloroacetate infusion followed by 45 minutes supine rest.  
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Figure 5.4 Blood lactate concentration.  Blood lactate concentration measured during 45 minutes of either intravenous saline or 
dichloroacetate infusion followed by 45 minutes supine rest, followed by 60 minutes of cycling at 75% VO2max after 3 days of high 
fat or normal diet.  * p<0.05 FD-DCA vs. CON and FD. 
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Figure 5.5 Plasma free fatty acid concentration.  Plasma free fatty acid concentration measured during 45 minutes of either 
intravenous saline or dichloroacetate infusion followed by 45 minutes supine rest, followed by 60 minutes of cycling at 75% VO2max 
after 3 days of high fat or normal diet.  *p<0.05 CON vs. FD and FD-DCA. 
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Figure 5.6 Muscle lactate concentration.  Muscle lactate concentration measured during 60 minutes of cycling at 75% VO2max 
following 3 days of high fat or normal diet, and 45 minutes of either intravenous saline or dichloroacetate infusion followed by 45 
minutes supine rest.  * p<0.05 vs. corresponding control time point.
0
10
20
30
40
50
60
70
CON FAT FAT/DCA
M
us
cl
e 
la
ct
at
e 
co
n
ce
n
tr
at
io
n
 
(m
m
o
l.(k
g 
dm
)-1 )
Rest 10 min 60 min
* 
* 
* 
 136 
 
Figure 5.7 Changes in muscle glycogen concentration.  Changes in muscle glycogen concentration during 60 minutes of cycling at 
75% VO2max following 3 days of high fat or normal diet, and 45 minutes of either intravenous saline or dichloroacetate infusion 
followed by 45 minutes supine rest.  * p< 0.05 vs. CON and FD. 
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Figure 5.8 PDC activation.  PDC activity prior to and during 60 minutes of cycling at 75% VO2max following 3 days of high fat or 
normal diet, and 45 minutes of either intravenous saline or dichloroacetate infusion followed by 45 minutes supine rest.  * p<0.05 vs. 
CON, SYV)'DQG&21, **p<0.05 vs. corresponding rest value. 
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Figure 5.9 Muscle acetylcarnitine concentration.  Muscle acetylcarnitine concentration during 60 minutes of cycling at 75% 
VO2max following 3 days of high fat or normal diet, and 45 minutes of either intravenous saline or dichloroacetate infusion followed 
by 45 minutes supine rest.  SYV&21SYV)'DQG&21 
0
2
4
6
8
10
12
14
16
18
20
CON FAT FAT/DCA
M
us
cl
e 
ac
et
yl
ca
rn
iti
n
e 
(m
m
o
l.(k
g 
dm
)-1 )
Rest 10 min 60 min
* 
 
 139 
may have been mediated by the raise in PPAR  DQGȖ-fold) transcription (Figs 5.11 
A and B).  3 days of high-fat feeding also increased the expression of FOXO1 (2-fold) 
after 10 minutes of exercise when compared to the control group (Fig 5.12), an effect that 
persisted at the completion of the exercise bout.  Exercise activated PDC in CON and FD, 
but this activation was blunted in the latter probably due to the sustained raise in PDK4 
and FOXO1 mRNAs. Furthermore, Pearson correlations between the expression of PDK4 
mRNA and FOXO and PPARs mRNA expression revealed that the highest significant 
relationship existed between PDK4 and FOXO1 mRNA expressions (r=0.71, p<0.0001, 
Fig 5.13A) followed by the relationship between PDK4 and PPAR  (r=0.44, p=0.007, 
Fig 5.13B).  There was however no significant difference between the r values compared 
above (p=0.31).  
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Figure 5.10 Muscle PDK4 expression.  Muscle PDK4 expression during 60 minutes of cycling at 75% VO2max following 3 days of 
high fat or normal diet, and 45 minutes of either intravenous saline or dichloroacetate infusion followed by 45 minutes of supine rest.  
* p < 0.05 vs. CON. 
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 Figure 5.11A Muscle PPARĮH[SUHVVLRQ  *p < 0.05 vs. CON. 
 Figure 5.11B 0XVFOH33$5ȖH[SUHVVLRQ 
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Figure 5.12 Muscle FOXO1 expression.  Muscle FOXO1 expression during 60 minutes of cycling at 75% VO2max following 3 days 
of high fat or normal diet, and 45 minutes of either intravenous saline or dichloroacetate infusion followed by 45 minutes of supine 
rest.  *p < 0.05 vs. CON.
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Control Fat Diet Fat Diet + DCA
Re
la
tiv
e 
FO
XO
1 
ex
pr
es
si
o
n
Rest 10 min 60 min
* 
 143 
 
Figure 5.13A Correlation between FOXO1 mRNA and PKD4 mRNA expression.   
 
Figure 5.13B &RUUHODWLRQEHWZHHQ33$5ĮP51$DQG3'.P51$H[SUHVVLRQ 
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Discussion. 
The primary aim of this study was to determine if DCA administration would reverse the 
VWLPXODWLRQRI33$5ĮDQG3'.H[SUHVVLRQVHHQGXULQJH[HUFLVHDIWHUKLJK-fat feeding.  
With respect to this aim, the results demonstrate that administration of DCA reversed the 
reduction in skeletal muscle PDC activity at the onset of exercise (Figure 5.8) following 
three days of high fat diet.  This effect was preserved during exercise, again reversing the 
blunted response of PDC activation following high fat feeding.  It is suggested that the 
dietary fat mediated reduction in PDC activation, and thereby CHO oxidation, during 
exercise may have been mediated by FOXO1 and PDK4 transcription, and this signalling 
was not blunted by contraction-mediated Ca2+ release. 
 
Infusion of DCA, as in Chapter 4, led to a reduction in the resting blood lactate 
concentration.  In contrast to the previous chapter, during exercise at 75%VO2max the 
lactate lowering effect was preserved during exercise.  This study supports previous 
research (Timmons et al, 1998a) that demonstrates the lactate lowering effect of systemic 
PDC activation in humans.  Three days of high-fat diet elevated plasma FFA 
concentrations, and DCA infusion did not significantly alter the plasma fatty acid 
concentration during rest or exercise.   
 
In support of previous research (Roberts et al, 2002a; Timmons et al, 1997; 1998a; 
Howlett et al, 1999a) demonstrating that DCA infusion is of benefit in overcoming 
metabolic inertia at the level of the PDC at the onset of contUDFWLRQ WKH µDFHW\O JURXS
GHILFLW¶SURSRVHGE\5REHUWVet al (2002a), the finding that DCA pre-treatment led to a 
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significant increase in muscle acetylcarnitine concentration in association with a 
reduction in muscle lactate concentration and a reduction in muscle glycogen breakdown 
during exercise is of note.   
 
These results demonstrate a stronger correlation between FOXO1 mRNA and PDK4 
P51$H[SUHVVLRQWKDQEHWZHHQ33$5ĮP51$DQG3'.P51$H[SUHVVLRQ)LJXUH
5.10A and B).  It is therefore suggested that FOXO1 transcription factor may be more 
important to controlling expression of PDK4 than the expression of PPARs in human 
skeletal muscle. It also appears that an acute bout of muscle contraction seems unable to 
revert the high fat diet FOXO1-mediated PDK4 inhibition on PDC activation. 
 
Peters et al (2001) demonstrated in humans fed a high fat/low carbohydrate diet that the 
upregulation of muscle PDK4 gene expression was mediated by direct binding of FOXO1 
to the promoter of the PDK4 gene.  It was suggested that FOXO1 would therefore have 
an important role in the regulation of whole body energy metabolism through its action 
on PDK4 mRNA expression and the expression of PDK protein (Furuyama et al, 2003).  
These results have also demonstrated an up-regulation of FOXO1 mRNA expression 
following three days of high-fat diet, with a corresponding reduction in PDC activity.  
This may suggest that FOXO is acting as a fuel substrate sensor in skeletal muscle.  
FOXO is known to tightly control the regulation of both muscle-specific RING finger 
protein 1 (MuRF-1) and muscle atrophy F-box protein (MAFbx; also known as atrogin-1) 
(Sandri et al, 2004; Stitt et al, 2004) and it may be through these pathways that it has its 
effects upon muscle energy metabolism, given that Koyama et al (2007) have recently 
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suggested that MuRF-1 acts as a connector of muscle energy metabolism and protein 
synthesis. 
 
Increase in fatty acid oxidation, induced by increased fat availability (Costill et al, 1977) 
or starvation (Wu et al, 1999), has been demonstrated to result in the activation of muscle 
PDK4.  This leads to phosphorylation and therefore inactivation of the PDC, which is the 
rate limiting step in muscle carbohydrate oxidation. In starvation, the mechanism by 
which this PDC inhibition occurs has been attributed to either an increase in fatty acid 
mediated activation of the transcription factor FOXO1 which leads to direct binding of 
this to the promoter region of the PDK4 gene (Furuyama et al, 2003), or through free 
fatty acid activatiRQRIWKH33$5ĮUHFHSWRU:Xet al, 2001) which results in an increase 
in the expression of PDK4 mRNA.  Research by Constantin-Teodosiu et al (2007) has 
recently demonstrated an increase in muscle PDK2 and PDK4 mRNA expression after 
administration of the P3$5į DJRQLVW *:  PJNJ-1) when compared to a 
control group, and this led to a doubling of the increase of PDK4 protein expression.  A 
VLJQLILFDQWLQFUHDVHLQȕ-hydroxy acyl CoA dehydrogenase activity was also noted within 
the same group, indicating a switch of metabolism towards lipid utilisation, and 
corresponding switch away from carbohydrate use, following treatment with GW610742. 
 
St. Amand et al (2000) demonstrated in healthy human volunteers that the resting 
reduction in PDC activation induced by 6 days of low carbohydrate diet was reversed, in 
part, by the availability of pyruvate during cycling exercise at 65% VO2max.  Given that 
DCA is thought to act upon PDK through its similarities to pyruvate (Halestrap, 1975), 
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these results would support the suggestion that PDC activity in skeletal muscle is closely 
regulated by intramuscular pyruvate concentrations, as seen in cardiac muscle. 
 
In conclusion, it is suggested that PDC inhibition, by any mechanism, may alter skeletal 
muscle selection of fuel for contraction towards fatty acid metabolism especially when 
fatty acid availability is increased.  This effect may explain some of the reported 
reduction of muscle contractile function seen following administration of PPAR agonists 
(Carley et al, 2003).  The reduction in PDC activation seen after high fat feeding has been 
reversed following pre-treatment with the PDK inhibitor DCA.  This inhibition would 
VHHP WR EH GXH WR DQ LQFUHDVH LQ SUHGRPLQDQWO\ )2;2 SURPRWHG EXW DOVR 33$5Į
stimulated PDK4 expression. 
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Chapter 6. 
 
GENERAL DISCUSSION 
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Overview. 
 
Much research into the function and regulation of the pyruvate dehydrogenase complex 
in skeletal muscle has been performed within the School of Biomedical Sciences, 
Nottingham (Timmons et al 1998a; b; 1996; Roberts et al 2005; 2001).  The present work 
follows on from this by further clarifying the physiological role of PDC with regard to its 
role in regulation of human skeletal muscle fuel metabolism.  Alteration of fuel selection 
at the onset of low intensity cycling exercise (<60% VO2max), using DCA infusion, was 
explored during repeated bouts of exercise.  Alteration of fuel selection at the onset of 
moderate intensity cycling exercise (75% VO2max), using high-fat/low-carbohydrate 
feeding, and its response to PDC activation was explored.  The link between lactate and 
the ventilatory threshold was explored using the PDK inhibitor dichloroacetate to reduce 
resting blood lactate concentration prior to incremental cycling exercise.   
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Principal findings 
 
i. Pre-treatment with DCA prior to low intensity (<60% VO2max) exercise 
does not overcome the minimal metabolic inertia present (Chapter 3). 
ii. The activation of PDC by dichloroacetate can persist during recovery 
between two bouts of exercise (Chapter 3). 
iii. A reduction in the resting blood lactate concentration prior to incremental 
exercise does not change the blood lactate concentration at or after the 
ventilatory threshold (Chapter 4). 
iv. DCA administration is able to reverse the PDC inhibition seen during 
exercise after high fat feeding (Chapter 5). 
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Metabolic inertia at the onset of low intensity exercise. 
The work presented in Chapter 3 has, for the first time, demonstrated that the 
administration of DCA prior to exercise at 60%VO2max does not alter the amount of PCr 
breakdown or lactate accumulation during the following exercise bout.  Prior to this work 
PDC activation prior to exercise at intensities below 60%VO2max has demonstrated that 
PDC activation overcame the metabolic inertia (increased PCr breakdown and lactate 
accumulation) residing at the level of PDC (Parolin et al, 2000; Timmons et al, 1998b).  
However the methods used in those studies result in an increased PCr breakdown when 
compared to bicycling in normoxic conditions, which would therefore increase the 
provision of non-oxygen dependent ATP regeneration.  DCA infusion, and the 
corresponding pooling of acetyl groups, would therefore be of benefit under these 
conditions.   
 
Researchers have demonstrated an upper threshold of exercise intensities at which DCA 
pre-treatment is of no benefit in overcoming the metabolic inertia present within skeletal 
muscle (Howlett et al, 1999b; Savasi et al, 2002; Bangsbo et al, 2002), which seems to 
correspond to the rate of maximal carbohydrate oxidation measured during exercise at 
similar intensities (Constantin-Teodosiu et al, 1991a; Howlett et al, 1998).  As the 
contribution from carbohydrate oxidation at low intensity exercise is minimal, I have 
sought to demonstrate the suggestion of Roberts et al (2002a) that there also exists a 
lower threshold of exercise intensity below which the degree of metabolic inertia is not 
significantly limiting to oxidative ATP provision at the onset of contraction. 
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The work in Chapter 3 suggests the existence of this threshold through the finding that 
although the infusion of DCA led to activation of PDC (4-fold increase in PDC 
activation; p<0.01) with a corresponding increase in muscle acetylcarnitine content (5.5 
fold increase; p<0.01) there was no reduction in PCr breakdown or lactate accumulation 
during either of the exercise bouts (within the limits of its statistical power).  Based upon 
the results of this chapter I would therefore suggest that in normoxic conditions at and 
below 60 %VO2max, the rate of activation of PDC is not rate limiting to ATP provision 
for contraction.  It is likely that exercise induced PDC generation, as well as contributions 
IURPIDWW\DFLGR[LGDWLRQDUHDEOHWRPDWFK$73SURYLVLRQZLWKWKHPXVFOH¶VPHWDEROLF
demands. 
 
At this exercise intensity fat derived fuel is preferentially used to provide energy for 
contraction (van Loon et al, 2001) and the increased use of carnitine stores to buffer the 
large amount of acetyl groups generated by the near-maximal activation of PDC at rest 
may have been limiting to fatty acid oxidation during exercise (Stephens et al, 2006).  At 
this exercise intensity increasing PDC flux may not only reduce the amount of free 
carnitine available for generation of energy from fat oxidation but also increase the use of 
carbohydrate derived ATP for contraction where such rapid provision of energy is not 
required.   
 
The increase in PDC activation seen in Chapter 5 led to an increase in muscle 
acetylcarnitine concentration at rest (p<0.05), as observed in Chapter 3 and previous 
studies (Timmons et al, 1998a; Roberts et al, 2002a).  At this exercise intensity 
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(75%VO2max) DCA pre-treatment was successful in overcoming metabolic inertia 
present at the onset of contraction, as demonstrated by the significant reduction in muscle 
glycogen breakdown following DCA pre-treatment.   
 
Following the work presented in Chapter 3, and in support of previous studies on 
skeletal muscle metabolic inertia, during cycling exercise at an intensity of 75% VO2max 
there was a reduction in metabolic inertia at the onset of contraction following DCA 
infusion.  Collectively these findings support the existence of metabolic inertia at the 
onset of skeletal muscle contraction, but suggest the presence of a lower threshold of 
exercise intensity below which pharmacological activation of PDC is not of benefit 
during the subsequent period of exercise. 
 
Persistence of the effect of dichloroacetate infusion upon PDC. 
Previous research has demonstrated a maximal effect of DCA infusion (in doses up to 
100mg.kg-1) on the PDC in human skeletal muscle for up to 15 minutes of contraction 
(Gibala et al, 1999; Parolin et al, 2000).  As well as its toxicity in chronic use (Stacpoole 
et al, 1979), this effect is also limiting to its suggested use as both a lactate lowering 
therapy in mitochondrial metabolic disorders and as a PDC activator in the therapy of 
conditions associated with premature skeletal muscle fatigue (such as PVD).   
 
However in Chapter 3 the results demonstrate persistence of PDC activation above basal 
as well as persistence of the enlarged acetylcarnitine pool available for contraction prior 
to the second bout of exercise, demonstrating that a one hour infusion of DCA (50 mg.kg-
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1) will activate PDC for more than a single bout of exercise over a period of at least 30 
minutes.  With interest into the protective metabolic effects of PDC activation during 
models of injury and ischaemia-reperfusion (Martin et al, 2004; Platz et al, 2007; Wilson 
et al, 2003) and the possibility of the PDC as a target for therapy in PVD or other 
conditions where premature skeletal muscle fatigue is present, this finding is of 
importance (see below). 
 
Dichloroacetate and the ventilatory threshold. 
If the ventilatory threshold is dependent on blood lactate concentration, then an alteration 
in the blood lactate concentration at the point of inflection in ventilation would be 
expected.  The lactate lowering effect of dichloroacetate infusion was used to explore the 
relationship between the lactate and ventilatory thresholds further during healthy human 
volunteers during incremental cycling exercise commencing at 50% VO2max. The 
findings of Chapter 4 demonstrate no alteration of the blood lactate concentration at and 
after the ventilatory threshold, despite a significant reduction in the net production of 
lactate during exercise (p<0.01).   
 
This chapter provides further evidence that the relationship between blood lactate 
concentration and the onset of the ventilatory threshold may not be as suggested by 
Wasserman et al (1973), in that accumulation of lactic acid within the muscles leads to an 
increase in the blood lactate concentration and a fall in pH.  Wasserman et al suggested 
that this reduction in blood pH is buffered, in part, by bicarbonate and the resultant 
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production of carbon dioxide increases VCO2.  The ventilatory threshold therefore occurs 
due to the increased rate of ventilation required to exhale the extra CO2 produced.   
 
However work by other researchers (McLellan and Gass, 1989; Busse et al, 1992) 
demonstrated in glycogen-depleted individuals, in whom lactate and the partial pressure 
of carbon dioxide are reduced, an increased or constant rate of ventilation when 
compared to control conditions suggesting that the ventilatory threshold is unlikely to be 
due to the simple action of peripheral chemoreceptors (Myers and Ashley, 1997). 
 
DCA infusion after high fat feeding. 
Reducing carbohydrate intake for several days inhibits PDC activation during exercise 
due to stimulatory effects upon PDK (Putman et al, 1993; Peters et al, 2001).  The 
molecular signalling pathways thought to account for this inhibition involve PPARs and 
FOXO, with their upregulation being linked to an increase in the expression of PDK4 
mRNA and protein in skeletal muscle (Wu et al, 2001).  DCA infusion is known to 
inhibit the activation of all the PDK isoforms (Whitehouse and Randle, 1973) but no 
researchers have investigated if the pharmacological activation of PDC was able to 
reverse the diet induced inhibition.   
 
The work presented in Chapter 5 demonstrates, for the first time, that pharmacological 
activation of PDC by dichloroacetate is able to reverse the inhibition of PDC activation 
by three days of high-fat/low-carbohydrate feeding.  PDC activation was reduced by 
high-fat feeding (p<0.05) but the infusion of DCA led to a 4-fold increase in resting PDC 
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activation (p<0.01) which remained elevated throughout exercise when compared to the 
fat-diet population.  This reduction in PDK activation occurred without a significant 
change in plasma free fatty acid concentration and persisted through contraction.  The 
results also demonstrated that ERWK )2;2 DQG 33$5Į expression are correlated with 
PDK4 mRNA expression, and there may be a trend towards a stronger correlation 
EHWZHHQ)2;2DQG3'.H[SUHVVLRQWKDQEHWZHHQ33$5ĮDQG3'.H[SUHVVLRQ 
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Future Work. 
 
The work presented above suggests further questions for future research to address.  The 
findings of this thesis highlight both the PDC as an important regulator of skeletal muscle 
fuel metabolism, and the use of dichloroacetate as a metabolic tool for the examination of 
PDC activation in human subjects.  A discussion of future avenues of research in this 
field follows:- 
 
Dichloroacetate-induced metabolic protection in ischaemia-reperfusion. 
Although the toxicity of dichloroacetate limits its possible therapeutic use in the 
treatment of chronic ischaemia-reperfusion, as seen in patients with intermittent 
claudication, the results presented in Chapter 3 indicate that the benefit in this group 
may not be as great as initially anticipated.  It is known within patients with more severe 
claudication that there exists a form of metabolic myopathy (Brass and Hiatt, 2000) 
which in a previous study responded to three days of carbohydrate supplementation 
(Barker et al, 2004).  Whether dichloroacetate administration, and its corresponding 
increase in skeletal muscle carbohydrate oxidation, is of benefit to patients with PVD has 
not yet been investigated.   
 
In cases where there is an acute episode of ischaemia-reperfusion without the likelihood 
of requirement for further therapy, such as during embolectomy following acute arterial 
occlusion or cross-clamping of the abdominal aorta prior to open surgical repair,  the 
toxicity of chronic dichloroacetate administration can be avoided.  The metabolic 
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protection has already been demonstrated to be of benefit in an animal model (Wilson et 
al, 2003), and in the case of elective surgery associated with increases in metabolic stress 
(e.g. during orthostatic liver transplantation (Shangraw et al, 2008)) it would seem as 
though dichloroacetate infusion prior to induction of anaesthesia is likely to be of benefit.  
 
FOXO as a fuel sensor? 
Within the discussion of Chapter 5 the suggestion that FOXO may have acted as a fuel 
substrate sensor for skeletal muscle metabolism was made.  Nakashima and Yakabe 
(2007) have demonstrated that activation of AMP kinase results in an increase in the 
expression of FOXO mRNA and protein in skeletal muscles.  AMP kinase has been 
HVWDEOLVKHGDVDPHWDEROLFµPDVWHUVZLWFK¶UHJXODWLQJJOXFRVHDQGOLSLGPHWDEROLVPDQGLW
may be that the changes in FOXO mRNA expression are a reflection of this effect.  With 
the finding of Barthel et al (2005) that FOXO proteins are involved in the mediation of 
LQVXOLQ¶VHIIHFWVRQPHWDEROLVPLWLVDSSDUHQWWKDW)2;2PD\SOD\PRUHRIDUROHWKDQLV
currently appreciated in the regulation of skeletal muscle fuel metabolism. 
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